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SUMMARY
 
Background 
Drugs for mental disorders have been on the market for more than 50 years, but there is still a 
need for more knowledge about the use and impact of these drugs in real-life conditions. 
Appropriate use of anxiolytics or hypnotics may relieve or reduce severe problems, whereas 
inappropriate use may represent problems of personal or public health.  
 
 
Aims
This thesis aims to study the epidemiology of anxiolytic and hypnotic drug use and, to a lesser 
extent, antidepressant drug use in the general population in Norway - in both cross-sectional 
and prospective cohort studies.  
Material and methods 
This thesis is based on data from 1) four health surveys done by the National Health 
Screening Service (now the Norwegian Institute of Public Health) in the counties of Østfold 
in 1985/1988 and Aust-Agder in 1986/1989, and in Oslo and Oppland/Hedmark in 2000-2001 
and 2) the Norwegian Prescription Database (NorPD). Information on drug use was at first 
collected from health surveys, later from NorPD. Mental health status was measured by the 
screening tool “Hopkins symptom checklist” (HSCL-10) that was part of the health surveys. 
Information on deaths was obtained from the Norwegian Causes of Death Register.   
 
 
Results 
 Daily users of anxiolytics or hypnotics showed higher crude mortality than non-users. 
However, after adjustment the difference was markedly reduced. 
 The majority of incident users of hypnotics received prescriptions for z-hypnotics 
(benzodiazepine related drugs) rather than benzodiazepines, the choice of 
benzodiazepines predicted most strongly by previous use of anxiolytics and male 
gender.  
 The main factor associated with use of anxiolytics or hypnotics among people with 
mental distress was the use of analgesics.  
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 The main factor associated with use of antidepressants among people with mental 
distress was not participating in the labour market.  
 Mental distress was a predictor of later use of anxiolytic drugs.  
 Women showed a higher proportion of use of psychotropic drugs than men, and there 
were also gender differences when studying mortality and incidence rates.  
 
 
Conclusion 
The health surveys offered selection bias and information bias that was eliminated when data 
were retrieved from NorPD. The health survey study populations were large enough to 
minimize random error, and from NorPD complete data were collected. The findings 
encourage general practitioners to be observant on mental distress as this is related to later 
anxiolytic drug use, that for selected populations is further associated with increased 
mortality. The gender differences observed for mortality, prevalence and incidence rates may 
lead us to question whether women suffer from more anxiety and depression than men, if they 
complain more, or if the truth is a combination of the two arguments.  
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1.0 BACKGROUND 
In Norway, prescriptions of anxiolytic and hypnotic drugs were filled by 6% and 8% of the 
population, respectively, in 2009 (1, 2). Appropriate use of these psychotropic drugs may 
relieve or reduce severe problems, whereas inappropriate use may represent problems of 
personal or public health. This thesis deals with some aspects of the epidemiology of 
psychotropic drug use in the general Norwegian population. 
 
1.1 General introduction  
Drug therapy is one of the most frequently used treatments of the majority of diseases and 
complaints, including mental disorders, in Western countries (3). Prior to marketing, every 
drug is subject to a randomized controlled trial (RCT), usually involving carefully selected 
patients over limited periods of time. The results of these trials form the basis for approval by 
regulatory bodies. Drugs for mental disorders have been on the market for more than 50 years 
but there is still a need for more knowledge about the use and impact of these drugs in real-
life conditions. Pharmacoepidemiological studies are post-marketing observational studies 
that can be performed independently of the drug marketing company and preferably as 
population-based studies. This thesis relies on population-based observational data from 
different parts of Norway.  
 
Pharmacoepidemiology can be defined as the application of epidemiological reasoning, 
methods and knowledge in the study of the uses and effects (beneficial and adverse) of drugs 
in human populations (4). The aim of pharmacoepidemiology is to describe, explain, control 
and predict the uses and effects of pharmacological treatments in a defined time, space and 
population. Pharmacoepidemiological research can be divided into two main fields; the first 
includes studies of variation in drug use in populations, drug use patterns, identification of 
predictors of use, and generation of hypotheses exploring variations of drug use. The other 
field includes case-control and cohort studies of for example side effects or adverse drug 
effects and studies investigating long-term effects of specific drugs in a population setting.  
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1.2 Mental disorders  
There are numerous ways to classify and define different mental disorders, most likely 
because the field of mental health is far from straight-forward. The following definitions of 
mental disorders refer to tools commonly used by Norwegian general practitioners (GPs) and 
psychiatrists.  
1.2.1 Definitions of the mental disorders relevant to this thesis 
Anxiety 
Fear, worry and anxiety are normal reactions to external and internal events that are perceived 
as threatening or dangerous (5). The mental anxiety experience is followed by physical 
symptoms such as palpitations, sweating or freezing (5). Anxiety disorders are characterized 
by excessive worry and trouble controlling worry, more than the somatic manifestations (6)  
 
Insomnia 
Insomnia can be defined as difficulty initiating or maintaining sleep for at least 1 month, 
which results in clinically significant distress or impairment in normal daytime functions (7). 
Insomnia may also be characterised by poor-quality or non-restorative sleep (7).  
 
Depressive disorders 
Depressive disorders are characterized by persistent low mood, loss of interest and enjoyment, 
neurovegetative disturbance and reduced energy, causing varying levels of social and 
occupational dysfunction (7). Depressive symptoms include depressed mood, anhedonia, 
weight changes, libido changes, sleep disturbance, psychomotor problems, low energy, 
excessive guilt, poor concentration and suicidal ideation (7).  
1.2.2 Measuring mental disorders or mental distress 
There are two main ways of measuring mental disorders or mental distress: by clinical 
diagnoses, or by self-reporting. A clinical diagnosis according to the International statistical 
classification of diseases and related health problems, 10th version (ICD-10) (8) or the 
Diagnostic and statistical manual of mental disorders, 4th version (DSM-IV) (6) can be given 
by GPs or psychiatrists, or estimated from the “Composite international diagnostic interview” 
(CIDI) (9) performed by trained interviewers. The less time-consuming method of self-
reporting on a questionnaire is usually preferred in population-based surveys. The participants 
then answer questions related to mental health; forming an instrument like “Hopkins symptom 
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checklist” (HSCL-25, HSCL-10 among others) (10), “Mental health index” (MHI) (11), 
“General health questionnaire” (GHQ) (12), the Gothenburg quality of life instrument (GQL) 
(13) or “Hospital anxiety and depression scale” (HADS) (14). A Norwegian study comparing 
HSCL-25 to CIDI concluded that HSCL-25 was acceptable as a screener for diagnosis of 
depression, but not of anxiety disorder (15).  
 
HSCL-10 and MHI-5 seem equally good as short instruments to measure mental distress and 
to predict mental disorders; however they both predict depression better than other diagnoses 
(16). HADS was found in a review to hold good case-finding properties for anxiety and 
depression; however no items regarding sleeping difficulties are included (17).  
 
1.2.3 Mental health in Norway and abroad 
In a Norwegian study using CIDI, the 12-month prevalence of all mental disorders was 33% 
and the life-time prevalence was 52% (18). In a survey carried out in the Norwegian county 
Nord-Trøndelag, 20.4% of the adult population had anxiety and/or depressive symptoms 
according to the HADS (19). From the same survey, the prevalence of sleep problems among 
patients in general practice was estimated to be 11.2%, of which almost two-thirds were 
believed to be caused by a medical condition and one-fourth by a mental condition (20).  
 
A World Health Organization (WHO) study of patients in general practice conducted in 14 
different countries, found that 24% had a current mental disorder; reaching ICD-10 criteria, 
whereas another 9% had a sub-threshold disorder (21). Being troubled by severe mental 
symptoms certainly can be considered a sign of poor perceived mental health but this is not 
the same as having a psychiatric diagnosis, although it may indicate an increased risk of 
developing one (22). Poor mental health is probably a strong predictor of psychotropic drug 
use, however not all individuals with mental distress will take psychotropic drugs (23, 24).  
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1.3 Psychotropic drugs 
1.3.1 Classification 
In this thesis I deal with a selection of drugs acting on the central nervous system (CNS): 
anxiolytics or hypnotics/sedatives, as well as antidepressants (Table 1). In the rest of this 
thesis I will use the term psychotropic drugs for these three drug groups. All drugs are 
classified according to the Anatomical therapeutic chemical classification system (ATC), and 
I will refer to this classification (25).  
 
Anxiolytic drugs (ATC code N05B) are agents that alleviate anxiety, tension, and anxiety 
disorders, promote sedation and have a calming effect without affecting clarity of 
consciousness (26). Anxiolytics prescribed in Norway are mainly benzodiazepines (BZDs) 
(2). Hypnotics and sedatives (ATC code N05C) are used to induce drowsiness or sleep or to 
reduce psychological excitement or anxiety (26). BZDs and BZD related hypnotics (z-
hypnotics) are the two main drug groups used for insomnia in Norway (2). Antidepressants 
(ATC code N06A) are mood-stimulating drugs used in the treatment of depressive disorders 
(26). Two-thirds of antidepressant drugs prescribed in Norway are selective serotonin 
reuptake inhibitors (SSRIs) (2).  
 
1.3.2 History 
The benzodiazepine era started globally with the release of chlordiazepoxide (Librium ®) and 
diazepam (Valium ®) in the early 1960s (27). The new drugs were soon preferred to the 
barbiturates, which had been used since the latter part of the 19th century. In 1978, Lader 
explained that this had happened because BZDs were more effective, safer in overdose, less 
liable to induce independence and had less effect on liver oxidizing enzymes (28). Five years 
later, Hollister stated “this is the benzodiazepine era”, although he simultaneously suggested 
that BZDs are not so remarkably different from the barbiturates (27). By the time of data 
collection for our first study (1985-1989), BZDs were practically the only anxiolytic and 
hypnotic drugs in Norway (29). Alternative hypnotic drugs were marketed in the 1990s, with 
the BZD related drugs z-hypnotics. In Norway, z-hypnotics are zopiclone and zolpidem and 
these drugs now dominate the market of hypnotic drugs (2, 29). Like BZDs, drugs for 
depression were first marketed in the 1960s (30). The non-selective monoamine reuptake 
inhibitors known as tricyclic antidepressants (TCAs) such as amitriptyline were, in the 1980s, 
supplemented by the sedative antidepressant mianserin; whereas the 1990s saw the massive 
introduction of SSRIs, but also other antidepressant drugs (Table 1) (31). 
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Table 1 A list of substances included in the thesis; with ATC codes and year of marketing 
authorisation and year of withdrawal, available in Norway in 1985-2007.  
Source: Norwegian Drug Wholesales statistics, Norwegian Institute of Public Health. 
    
ATC code Substance Marketing Withdrawal 
N05B ANXIOLYTICS     
N05BA Benzodiazepine derivatives     
N05BA01 Diazepam 1963   
N05BA04 Oxazepam 1987   
N05BA12 Alprazolam 1994   
N05BB Diphenylmethane derivatives   
N05BB01 Hydroxyzine 1964  
N05BE Azaspirodecanedione derivatives   
N05BE01 Buspirone 1992  
N05C HYPNOTICS AND SEDATIVES     
N05CD Benzodiazepine derivatives     
N05CD02 Nitrazepam 1965   
N05CD03 Flunitrazepam 1984   
N05CD05 Triazolam 1983 1991 
N05CF Benzodiazepine related drugs     
N05CF01 Zopiclone 1994   
N05CF02 Zolpidem 2000   
N06A ANTIDEPRESSANTS     
N06AA Non-selective monoamine reuptake inhibitors   
N06AA02 Imipramine 1982 1999 
N06AA04 Clomipramine 1970   
N06AA06 Trimipramine 1981   
N06AA09 Amitriptyline 1961   
N06AA10 Nortriptyline 1965   
N06AA12 Doxepin 1970   
N06AB Selective serotonin reuptake inhibitors     
N06AB03 Fluoxetine 1996   
N06AB04 Citalopram 1995   
N06BA05 Paroxetine 1993   
N06BA06 Sertraline 1996   
N06BA08 Fluvoxamine 1990   
N06BA10 Escitalopram 2002   
N06AG Monoamine oxidase A inhibitors     
N06AG02 Moclobemide 1990   
N06AX Other antidepressants     
N06AX03 Mianserin 1982   
N06AX06 Nefazodone 1996 2003 
N06AX11 Mirtazapine 2000   
N06AX12 Bupropion 2000   
N06AX16 Venlafaxine 1999   
N06AX18 Reboxetine 1999   
N06AX21 Duloxetine 2004   
Drugs available as injections only are not included.    
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1.3.3 Pharmacology and clinical implications 
Benzodiazepines
The major molecular targets of the BZDs are inhibitory neurotransmitter receptors directly 
activated by the amino acid gamma-aminobutyric acid (GABA) (30). The major type of 
GABA receptor in the brain, termed the GABAA receptor, is an integral membrane chloride 
channel that mediates most of the rapid, inhibitory neurotransmission in the CNS. BZDs bind 
to this receptor/ion channel complex and allosterically modulate its activity (30). The 
conformational change in the GABAA receptor increases the affinity of GABA binding, thus 
enhancing the actions of GABA on the Cl- conductance of the neuronal membrane (32). 
Increasing the membrane potential of the neurone inhibits neuronal firing, and this reduces 
arousal of the cortical and limbic systems in the CNS (33). BZDs can cause cognitive (34) 
and psychomotor (35) impairment and have residual effects on the day following intake (36). 
BZDs carry the risk of drug abuse, dependence (37, 38) and the development of tolerance 
(39).  
It is worth mentioning the indistinct boundary between anxiolytics and hypnotics. Anxiolytics 
may be used to aid sleep and thus be used as a hypnotic drug. People may change from one of 
these drug groups to the other without changing diagnosis. Their mechanism of action is 
similar. However, there are differences in their pharmacokinetics. The BZDs used in Norway, 
both anxiolytics and hypnotics, have long elimination half-lives. Abroad there are also BZD 
hypnotics with shorter half-lives which are preferred to avoid daytime sedation. Because of 
lack of relevance to this thesis, I have chosen not to describe the pharmacokinetics of BZDs in 
more detail here but refer to the literature (30).   
 
Z-hypnotics 
Like BZDs, the z-hypnotics bind at GABAA receptors. However, z-hypnotics have a shorter 
onset and duration of action which is favourable unless sleep maintenance is the main 
problem (40). Noticeably, the drugs have different affinity for the GABAA receptor subtypes. 
The GABAA receptor selectivity is low for BZDs, medium for zopiclone and high for 
zolpidem (40, 41). The more selective receptor profile of zolpidem is expected to cause fewer 
adverse effects on sleep architecture (42), myorelaxation and respiratory depression (43), but 
current research still concludes that the different z-hypnotics are quite similar in clinical use 
(40). Reviews have stated that zopiclone and zolpidem can be abused (44), however the abuse 
liability is lower than that observed with BZD hypnotics (45).  
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Antidepressants 
Most of the drugs used in the treatment of depression, like SSRI, TCA and others, in different 
ways inhibit the reuptake of serotonin and/or noradrenaline; resulting in increased release of 
the neurotransmitter(s) (32). These drug effects suggest that depression might be associated 
with decreased neurotransmitter activity; however some compounds like mianserin are 
antidepressant although they don’t affect reuptake, while cocaine blocks reuptake without 
being an antidepressant (32). Antidepressants are also used for other indications, such as 
anxiety and obsessive-compulsive disorder.  
 
1.3.4 Guidelines, therapeutic recommendations and common practice 
In Norway in 1990, the Directorate of Health issued, “Guide to the prescription of addictive 
drugs” (46). Revised and updated guidelines were published in 2001 by the Norwegian Board 
of Health Supervision with the modified title, “Addictive drugs. Prescribing and Justification” 
(47). After the reorganization of the Norwegian health administration from 2002 it was 
decided that the newly created Directorate of Health and Social Affairs (later renamed the 
Directorate of Health) would be responsible for issuing technical directives and guidelines. 
No new guidelines on the use of addictive drugs have been issued. 
 
Norwegian therapeutic recommendations suggest that BZDs should be used as anxiolytics for 
shorter periods of time only, and, as hypnotics, intermittent use with the lowest possible dose 
is preferred (48, 49). Non-pharmacological treatment is the first choice in light to moderate 
anxiety and in chronic primary insomnia (>3 weeks), and as a supplement to z-hypnotic drugs 
in acute situational insomnia (49). This is mainly in concordance with guidelines in the UK 
and the USA (50-52).   
 
There are studies discussing guidelines and/or common prescription practice both in Norway 
(53) and abroad (40, 44, 45, 50, 54-56). Some review authors have (clearly or vaguely) 
recommended the use of z-hypnotics in preference to BZD hypnotics (42, 45, 55), while 
British guidelines recommend the use of BZD hypnotics with a short terminal elimination 
half-life (not marketed in Norway) in preference to z-hypnotics because of equal effects and 
lower prices (52). 
 
In Norway, more than 80% of BZDs are prescribed by GPs (57). Several studies have covered 
GPs’ or psychiatrists’ attitudes to and prescribing of BZD anxiolytics, BZD hypnotics and/or 
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z-hypnotics (20, 58-62). At the time of initiating BZD prescription, some GPs seem to feel 
overwhelmed by the psychosocial problems of patients, and find BZDs to be “the lesser evil” 
(58). Regarding duration of treatment, both GPs and psychiatrists may agree with guidelines, 
however they find them hard to follow (61, 63). GPs’ knowledge about z-hypnotics has been 
questioned, both in Norway and abroad (59, 61-63). In a recent national survey of all GPs 
practising in Norway, sleep hygiene advices were the most commonly used treatment 
strategy, whereas hypnotics were believed to have the best short-term efficacy (20). 
Antidepressants were considered by the GPs to be the best option for long-term management 
of sleep problems. The authors mention as one possible explanation of this finding that 
depression very often coexists with insomnia: alleviating depressive symptoms are likely to 
also reduce sleep problems (20).  
 
The use and misuse of BZDs is disputed. However, the concept of inappropriate use must be 
approached with caution. Strictly speaking it is defined as use that does not meet clinical 
needs, in doses that do not match individual requirements, for an inadequate period of time, or 
at a cost that is not acceptable for the patient or the community (64).
 
At population level, however, inappropriate use may be suspected if there are important 
unexplained differences, for example, in the use of BZDs between different population 
groups. One way to explore this is to examine the use of BZDs in relation to specific mental 
health conditions (24).
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1.4 Population-based sources of data on psychotropic drug use at an 
individual level in Norway 
The possibility of doing high quality research on drug exposure in Norway has steadily 
improved, as information on drug use has been collected, step by step, in more detail, and 
closer to the actual user. There has been a development from annual reports of drug sales as 
reported from wholesalers, via health surveys, to the current nationwide prescription database.  
 
1.4.1 Population-based health surveys  
Since the early 1970s, a series of population-based health surveys have been conducted by the 
National Health Screening Services, now part of the Norwegian Institute of Public Health, in 
different Norwegian counties. These health surveys have collected information about drug use 
at an individual level (65). The questions about drug use in general have developed from 
simple questions with only a dichotomous outcome, to answer alternatives specifying the 
frequency of drug use (66). The drug categories included have also developed, from questions 
about the use of antihypertensive drugs only to a battery of drug categories (67).  
 
Most of the health surveys included a physical examination with, for example, blood pressure 
measurement and blood samples. At the physical examination, a supplementary questionnaire 
was usually handed out. Questions about anxiolytic and hypnotic drug use were at first 
included in the supplementary questionnaire, leading to a lower response rate than if they had 
been part of the main questionnaire (68). However, from the year 2000, questions on 
anxiolytic and hypnotic drug use were included in the main questionnaires (67).  
 
1.4.2 The Norwegian Prescription Database  
The Norwegian Prescription Database (NorPD) covers the entire nation (4.8 million 
inhabitants) (69). From January 1st 2004, all pharmacies in Norway have been legally obliged 
to provide data on all dispensed prescriptions to the Norwegian Institute of Public Health. 
NorPD contains information on all individuals not living in institutions who have received 
prescription drugs dispensed at pharmacies (70). All prescriptions from ambulatory care are 
stored in the database. Antidepressants are covered by the national reimbursement system in 
Norway, whereas anxiolytics and hypnotics are not. However, in contrast to prescription 
databases in Denmark and Finland, NorPD includes full information about non-reimbursed 
drugs in addition to the reimbursed (71).  
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All drugs in Norway are classified according to their main substance in ATC, which is useful 
in order to retrieve and analyse data about psychotropic drugs on a substance level. Even if 
identical substances are marketed as different, competing drug trademarks; in different 
packages and with different sales codes, ATC gathers all identical substances under one code. 
Another useful research tool is the defined daily dose (DDD): The assumed average 
maintenance dose per day for a drug, used for its main indication in adults (25). NorPD offers 
the number of DDD for each prescribed drug substance to each person; making it possible to 
calculate the amount of the drug prescribed and the duration of treatment for each individual. 
 
NorPD does not include medications for individuals in hospitals and nursing homes. 
Estimates of the use of psychotropic drugs among people over 70 years will be low because a 
significant proportion will be in nursing homes, from where data is only available on an 
institutional level.  
 
1.5 The history of psychotropic drug use in Norway 
1.5.1 Anxiolytics and hypnotics 
Aggregated level 
BZDs dominated the sales of anxiolytics and hypnotics from the 1960s until the mid 1990s 
(29). Sales of benzodiazepines increased sharply in Norway in the 1960s and 1970s. In the 
1980s, there was an increasing focus on the use of benzodiazepines and problems associated 
with negative effects (29). The sale of anxiolytics (N05BA) was reduced from 29 DDD/1000 
inhabitants/day in the early 1970s to 17 DDD/1000 inhabitants/day in 1997 (72). This was 
followed by a small increase. However, since 2006, sales have once more decreased and been 
below 20 DDD/1000 inhabitants/day (2). 
 
Wholesaler statistics for anxiolytics and hypnotics from 1985 to 2009 are shown in Figure 1.  
For BZDs used as hypnotics, there was a peak in the use in the period 1984–1990. The peak 
of 43 DDD/1000 inhabitants/day (1989) and the following decline to 25 DDD/1000 
inhabitants/day (1994) were due to the introduction and withdrawal of the hypnotic drug 
triazolam (Halcion®) in 1983 and 1991, respectively (29). In 1994, z-hypnotics were 
introduced. After this, the sale of BZD hypnotics was further reduced. However, z-hypnotics 
contributed to the total sale of hypnotics again rising to above 40 DDD/1000 inhabitants/day 
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since 2005 (2, 29). Total sales of anxiolytics and hypnotics levelled out somewhat in 2008 
and 2009 after several years of increase (29).  
 
Figure 1 Sales of BZD anxiolytics (ATC code N05BA), BZD hypnotics (N05CD) and z-hypnotics (N05CF) in 
Norway 1985-2009. Source: Norwegian Drug Wholesales statistics, Norwegian Institute of Public Health.  
ATC/DDD version 2010. 
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Individual level 
A study from a rural part of Norway (Værøy and Røst in Lofoten) in 1971, showed that 
anxiolytics and hypnotics were prescribed to 17% of the women and 11% of the men (73). In 
1980, the corresponding total number for both genders was 25% in Østfold (74), a county still 
known to have an extensive consumption of these drugs (2). The studies from 1971 and 1980 
showed that two thirds of BZD users were women and that the prevalence of use increased 
with age (73, 74).  
 
The establishment of the nationwide prescription database in 2004 made it possible to present 
individual data on the use of anxiolytics and hypnotics for the whole country. Data from 
NorPD shows that during each of the years 2004-2009, 8% of the inhabitants filled 
prescriptions for hypnotics, and the percentage increased slowly (1). During the past six years, 
the number of inhabitants filling prescriptions for BZD hypnotics (N05CD) decreased, while 
the corresponding number for z-hypnotics (N05CF) increased a bit more, explaining the 
overall rise (1).  
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To describe use on an individual level, I will use “one year prevalence”, the number of users 
who filled at least one prescription during a certain year per 100 inhabitants in the population 
sample; in this case the whole of Norway. Figure 2a shows one year prevalence of use of 
BZD hypnotics in Norway in 2004-2009 for adult men in 10-year age groups. The prevalence 
increases with increasing age and decreases annually within the age groups. The same 
tendencies are shown for women in Figure 2b.  
 
Figure 2a One year prevalence (%) of use of benzodiazepine hypnotics among adult men in Norway 2004-2009.  
Source: NorPD. 
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Figure 2b One year prevalence (%) of use of benzodiazepine hypnotics among adult women in Norway 2004-
2009. Source: NorPD. 
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During 2004-2009, the prevalence of z-hypnotics in Norway increases or is practically stable 
within each age group for both men and women (Figure 3a and 3b). Comparing the age 
groups, the prevalence increases with increasing age.  
 
 
Figure 3a One year prevalence (%) of use of z-hypnotics among adult men in Norway 2004-2009. Source: 
NorPD. 
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Figure 3b One year prevalence (%) of use of z-hypnotics among adult women in Norway 2004-2009. Source: 
NorPD. 
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1.5.2 Antidepressants 
Aggregated level 
The total sale of antidepressants (N06A) has increased every year except one (2005) since 
they were marketed (2, 72), however the development for each category of antidepressants 
deviates from this. The sale of TCA has decreased slowly and the sale of SSRI has increased 
rapidly since the introduction of SSRI in 1990. Wholesaler statistics for antidepressants from 
1985 to 2009 are shown in Figure 4.  
Figure 4 Total sales of antidepressants (ATC code N06A), dominated by SSRI (N06AB) and the tricyclic 
antidepressants (N06AA) in Norway 1985-2009. Source: Norwegian Drug Wholesales statistics, Norwegian 
Institute of Public Health. ATC/DDD version 2010. 
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A Norwegian study of the sale of SSRI and other antidepressants 1990-2004 showed large 
changes in the sale of each antidepressant drug during the period, most likely as a 
consequence of new drugs being marketed and side effects of existing drugs being reported 
(31).  
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1.5.3 Norway compared to other countries 
Psychotropic drug sales data from the Nordic countries are compared by Nordic Medico 
Statistical Committee by the use of DDD/1000 inhabitants/day (75). Norway is most often 
placed in the middle of the consumption statistics. In 2007, Finland and Iceland had a higher 
consumption of BZD anxiolytics than Norway, whereas Denmark and Sweden had a lower 
consumption. The latter two countries were the only ones to show a reduction in BZD 
anxiolytics since 1995.  
 
Regarding BZD hypnotics, Finland was the highest consumer in 2007; with approximately 
twice as many DDD/1000 inhabitants/day as Iceland, whereas Denmark, Norway and Sweden 
consumed even less. Noticeably, all the Nordic countries reduced the consumption of BZD 
hypnotic drugs by at least 60% between 1995-2007, except for Finland; showing a stable 
level.  
 
For z-hypnotics, Iceland showed the highest consumption in 2007; and nearly twice that of 
Norway, Finland and Sweden. Denmark was at the bottom consuming only one-third as much 
as Iceland. All five countries have shown a marked increase in the consumption of z-
hypnotics since they were introduced, however the increase has been moderate during the past 
few years.   
 
For antidepressants in general, Iceland had the highest consumption in 2007, whereas Norway 
had the lowest; and this also counted for SSRI alone. All the Nordic countries showed a 
decreasing consumption of TCA and an increasing consumption of SSRI during 1995-2007.  
 
Surveys in six European countries in 2001-2003 reported a prevalence of psychotropic drugs 
ranging from 6% to 19%, however there were no separate data for anxiolytics, hypnotics or 
antidepressants (76). 
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1.6 Previous epidemiological findings 
1.6.1 Benzodiazepine use and mortality  
The use of BZDs and later mortality has been studied in general populations (77-82) and in 
subgroups such as patients dependent on prescription drugs (83), drug misusers (84) or 
drugged drivers (85, 86). The sources of information on drug use were questionnaires, 
interviews, diagnosed dependency or results from blood tests taken from drivers. The 
definition of BZD use in general populations varied, as did the population sample size and the 
period of follow-up. Some authors have found increased all-cause mortality after BZD use 
(78-80, 83-86), whereas others have not (77, 81, 82).  
 
1.6.2 Hypnotic drug use 
The use of hypnotic drugs has been studied earlier both in Norway (87-90) and abroad (75, 
76, 91-95), sometimes as part of studies on the use of BZDs or psychotropic drugs in general. 
The sources of information on drug use have been questionnaires, interviews of GPs or 
general population, journal data, prescription data or sales data.  
 
In Norway, a study using data from NorPD showed that 7.9% of the population received at 
least one prescription of a hypnotic drug in 2005 (88), comparable to the 6.9% found from 
telephone interviews a few years earlier (89). In a survey in the Norwegian county Nord-
Trøndelag, 3.5% of the participants answered on a questionnaire that they had used sleep 
medications and 3.1% had used sedatives, in both cases on a daily or almost daily basis during 
the past 12 months, but the authors explained that there was a possible overlap because the 
categories were not mutually exclusive (90). In Norway, wholesaler statistics show an 
increasing annual amount of hypnotics sold (96), however a change in the sales of different 
hypnotic drugs was observed after restrictions in the prescription status of flunitrazepam in 
2003 (87).  
 
Abroad, studies on long-term use of BZDs or z-hypnotics are easy to find (97-100), whereas 
studies on incident use; the early phase of every history of long-term use, are scarce. Some 
authors have studied the aggregated incidence of BZD hypnotics, z-hypnotics and BZD 
anxiolytics (91, 94). 
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Recent studies have found z-hypnotics to be prescribed more often than BZDs (92, 95). 
Concomitant use of any other psychotropic drug was associated with higher use of BZDs with 
medium acting time, but lower use of z-hypnotics (92). When studying zopiclone and 
zolpidem separately, the drugs showed divergent patterns: concomitant use of any other 
psychotropic drug was associated with lower use of zolpidem, whereas concomitant use of 
antidepressants was associated with higher use of zopiclone (92).  
 
As far as I know, predictors of which hypnotic drug is chosen at the start of insomnia 
treatment have not been studied.
 
1.6.3 Factors associated with psychotropic drug use 
In cross-sectional studies, the use of one or more categories of psychotropic drugs in the 
general population has been shown to be associated with certain health, lifestyle and 
socioeconomic factors: female gender (24, 93, 101), increasing age (24, 93, 101), poor self-
reported somatic health (24, 93, 101-103), diagnosed concurrent chronic somatic morbidity 
(104), help seeking for mental/emotional problems (101, 105), mental distress indicators 
(106), psychological pathology (24, 93, 101), psychiatric co-morbidity (104), the use of 
analgesics (107), the prescription of other psychotropics (108), smoking (105, 109), heavy 
drinking (110), marital status (111), low educational level (93, 101, 112), low income (111) 
and non-participation in the labour market (110, 113).  
 
The sources of information on drug use have been questionnaires, interviews, GPs’ medical 
records or journal data. As far as I know, there has not been any prospective cohort study 
investigating mental distress as a predictor of anxiolytic drug use.  
 
The use of psychotropic drugs among people with mental distress or mental disorders has 
been studied both for institutionalized (114-116) and non-institutionalized populations (23, 
24, 76, 90, 101, 104, 107, 108, 117). 
The use of psychotropic drugs among people with mental distress in non-institutionalized 
populations has ranged from 15% (23) to 48% (101); however this variation may partly be 
explained by different measures of both mental distress and drug use. One study showed that 
men scoring over the GHQ-30 score threshold (>5) for psychiatric morbidity had a risk of 
receiving a psychotropic drug prescription 49 times higher than the general sample (117).  
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Studies on predictors of BZD use are less common, as most longitudinal studies focus on 
long-term and chronic use of BZDs (98, 99). Research on predictors of BZD use in non-
institutionalized populations with mental distress symptoms rather than mental disorders is 
lacking.  
1.7 Why study anxiolytics and hypnotics? 
Appropriate use of BZDs can be defined as use by indication – mainly as treatment for 
anxiety or sleeping problems. However, the use of BZDs can cause cognitive (34) and 
psychomotor (35) impairment and carry the risk of drug abuse and dependence (37, 38). 
Therefore, the comprehensive use of BZDs has been controversial (118, 119) and the drugs 
are constantly being discussed and studied. BZDs are known to be habit forming and they 
may cause dependency (37, 38, 120) and adverse drug reactions (39, 120, 121). BZD use 
increases the risk of falls among the elderly (122). Both BZDs and z-hypnotics are known to 
be traffic-hazardous drugs (35), and impaired drivers increase the risk of road traffic accidents 
(123). Taking into account that more drivers are apprehended with BZDs than with heroin or 
amphetamine, one can ask whether BZDs are a greater threat to traffic safety (124). 
Apprehension on suspicion of driving under the influence of drugs, combined with detection 
of BZDs or z-hypnotics in the blood, seems to indicate an elevated risk of premature death 
(85).  
 
For z-hypnotics, there are fewer and milder described adverse effects compared to BZDs. 
Zopiclone may cause a bitter taste, whereas zolpidem can cause CNS-associated adverse 
effects such as headache and daytime somnolence (41). Antidepressants may cause adverse 
effects that can be difficult to separate from the depressive diagnosis: dry mouth, fatigue, 
dizziness, headache and reduced libido (125). A Norwegian study showed a slightly increased 
risk of being involved in a road traffic accident after receiving a prescription for any 
antidepressant drug (126). 
 
Inappropriate use of psychotropic drugs represents a personal and public health problem. The 
economic aspect is worth mentioning, as drugs which affect the CNS (ATC code N) currently 
have the second highest per cent share per ATC group of the total sales in Norway; 17 % 
(measured in NOK) (2).  
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Problematic aspects of the use of anxiolytics and hypnotics are well documented, and the 
epidemiology of use in general has been studied thoroughly. On the other hand, most existing 
studies tend to focus on long-term use, abuse, use among the elderly, use in the general 
population or in institutions. We lack knowledge about subgroups of the general population, 
such as, non-institutionalised middle-aged people who have symptoms of mental distress 
although not necessarily enough to be diagnosed as having a mental disorder.     
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2.0 AIMS OF THE STUDY 
The main objective of this thesis was to study the epidemiology of anxiolytic and hypnotic 
drug use and, to a lesser extent, antidepressant drug use in the general population in Norway – 
in both cross-sectional and prospective cohort studies.  
 
The specific research questions were:  
 Does anxiolytic and hypnotic drug use in the 1980s predict higher mortality in a 
general middle-aged population? (Paper I) 
 Does co-medication with other drugs predict the type of hypnotic drug chosen in 
incident users? (Paper II)  
 What health, lifestyle and sociodemographic factors are associated with anxiolytic, 
hypnotic and/or antidepressant drug use among people with mental distress? (Paper 
III)  
 Do mental distress symptoms predict later anxiolytic drug use? (Paper IV) 
 Are there gender differences in the epidemiology of anxiolytic, hypnotic and 
antidepressant drug use? (Papers I-IV) 
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3.0 MATERIAL AND METHODS 
3.1 Sources of data and study population 
This thesis is based on data from four health surveys and the Norwegian Prescription 
Database: surveys done by the National Health Screening Service (now the Norwegian 
Institute of Public Health) in the counties of Østfold in 1985/1988 and Aust-Agder in 
1986/1989 (paper I) (68), and in Oslo and the counties of Oppland/Hedmark in 2000-2001 
(papers III and IV) (127, 128) and the Norwegian Prescription Database (papers II and IV) 
(1). Both genders were included in all the study populations. The materials used in the 
different papers are presented in Table 2.
 
Table 2 The study populations in papers I-IV  
       
Area of study 
Study 
period
Information
on drug use 
Age at 
baseline  
Respondents 
(Response rate %) 
Female (% of 
respondents) Paper
Østfold and 
Aust-Agder 
1985/1988, 
1986/1989 
Health 
survey;  40-42 23 154 (76.3) 11 910 (51.4) I 
  
supplemental 
questionnaire       
Oslo and 
Oppland/Hedmark 2000-2001 
Health 
survey;  
30, 40, 45, 
59/60, 75/76 31 274 (49.5) 17 186 (55.0) III, IV
  
main 
questionnaire       
Norway 2004-2007 
Prescription 
database All ages 
All individuals who filled 
prescriptions II, IV 
 
3.1.1 Health surveys 
Health surveys in Østfold (1985/1988) and Aust-Agder (1986/1989)  
These population-based health surveys were carried out in the counties of Østfold in 1985 and 
1988 and in Aust-Agder in 1986 and 1989. Østfold and Aust-Agder are counties characterised 
by a high-population use of anxiolytic and hypnotic drugs. In total, 30 354 subjects aged 40-
42 years were invited to participate (68). The health surveys were part of a project that started 
with health surveys in other counties in the 70s, and was directed towards cardiovascular 
disease (129, 130). Two examinations, targeting two different generations of people 40-42 
years at the time of the survey, were carried out with a 3 year interval. One self-administered 
questionnaire was part of the letter of invitation. The questions on drug use were included in 
the supplementary questionnaire, which was handed out at the medical examination, and 
returned in pre-stamped envelopes. The questionnaires provided information on various 
health, lifestyle and socioeconomic factors, and are found in Appendix I.  
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In total, 23 154 individuals attended the medical examination, giving a total response rate of 
76.3%. Of these, 19 032 individuals responded the supplementary questionnaire (9111 men 
and 9921 women). 
 
Among these 19 032 individuals, the question on anxiolytic or hypnotic drug use was 
answered by 85% of the men and 83% of the women.  We wanted to study a healthy 
population, and excluded individuals suffering from or with symptoms indicating heart 
infarction, angina pectoris, diabetes and stroke before hazard ratios were estimated. This was 
done because such individuals already had a possible elevated risk of death. 
 
Health Surveys in Oslo (2000-2001) and Oppland/Hedmark (2000-2001) 
These population-based health surveys were carried out in the counties of Oslo, Oppland and 
Hedmark in 2000-2001. The Oslo Health Study (HUBRO) (128) and the Oppland and 
Hedmark Health Study (OPPHED) (127) were performed in a very similar way, but whereas 
HUBRO covers an urban population (Oslo is the capital of Norway), OPPHED covers a rural 
population, as Oppland and Hedmark do not host any of the 20 biggest towns in Norway. An 
invitation to attend a health screening was sent to all individuals born in 1924 (HUBRO only), 
1925, 1940, 1941 (HUBRO only), 1955, 1960 and 1970 (127, 128). A total of 63 160 citizens 
were invited. Of these, 31 274 individuals attended a physical examination and/or filled in at 
least one questionnaire, giving a total response rate of 49.5%.  
 
For our study (papers III and IV), only individuals born 1940, 1941, 1955 and 1960 were 
selected, that is, those who were about 40, 45 and 60 years old. The drug use questions were 
included in the main questionnaire (131-133), which was part of the invitation letter. The 
main questionnaires in HUBRO and OPPHED were identical and can be found in Appendix 
II. Several of the questions have been evaluated or validated and deemed acceptable (65). The 
National Population Register was used to identify eligible subjects.  
 
3.1.2 Health or population registries 
The Norwegian Prescription Database (NorPD) 
Data on anxiolytic drug use for paper IV were taken from the NorPD which covers the entire 
nation. NorPD contains information on all prescriptions to individuals not living in 
institutions, who have received prescription drugs dispensed at pharmacies (70). All 
prescriptions from ambulatory care, whether publicly reimbursed or not, are stored in the 
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database. Anxiolytics and hypnotics are prescription drugs in Norway, and thus the drug use 
data for this thesis cover the whole Norwegian non-institutionalised population.  
 
The data collected for our study were patient unique identifying number (encrypted), sex, age, 
the date of dispensing and drug information (ATC code and DDD). Information on drugs 
studied is given in the Variables section. The study period was 2004-2006 (paper II) and 
2004-2007 (paper IV). In paper II, all individuals of age 18-69 years were selected, whereas 
in paper IV, age cohorts that were 40-41, 45-46 and 59-61 years old at baseline were selected.   
 
The National Population Register 
Information about marital status (papers I and IV) was retrieved from the National Population 
Register (134).  
 
The Norwegian Causes of Death Register 
Number of deaths for different groups and both sexes were obtained from the Norwegian 
Causes of Death Register (135). In paper I, this was used to calculate mortality. In paper IV, 
this was used to exclude individuals who died or emigrated between baseline (2000-2001) and 
the release of NorPD (January 1st 2004). During further follow-up (2004-2007) information 
on deaths was available from NorPD.  
3.2 Design 
Table 3 shows the study design used in each of the papers.  
 
Table 3 Design in papers I-IV     
  
  Paper number 
  I II III IV 
Cohort study x x   x 
Cross-sectional study     x   
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3.3 Variables 
3.3.1 Dependent variables 
The dependent variables used in the different papers are shown in Table 4. 
 
Table 4 Dependent variables used in papers I-IV      
      
Domain Examined ATC code Paper number 
      I II III IV 
Mortality Hazard ratio    - x       
Drug use Incident users; z-hypnotics versus BZD hypnotics N05CF/N05CD   x     
  Use of anxiolytic drugs N05B     x x 
  Use of hypnotic drugs N05C   x x   
  Use of antidepressants N06A     x   
 
Mortality
For the dependent variable “hazard ratio” (HR) in paper I, information about deaths was 
retrieved from the Norwegian Causes of Death Register that is kept by Statistics Norway (69). 
The number of observation years was calculated for each person from the time of medical 
examination to either the time of death, the time of emigration or the end of follow-up period 
(27.01.2006).  
 
Drug use 
This thesis deals mainly with anxiolytics (papers I, III and IV) and hypnotics (papers I, II and 
III). In paper III, antidepressants are also included. An overview of the substances on the 
Norwegian market is given in Table 1. Information on drug use as dependent variables was 
collected from health surveys (paper III) or NorPD (papers II and IV).  
Incident users in 2006 of BZD hypnotics or z-hypnotics were identified from NorPD for paper 
II. We identified incident users as individuals filling a prescription in 2006, without any 
recorded prescription of any hypnotic substance during the 730 days (2 years) prior to that 
prescription. BZD hypnotics were nitrazepam or flunitrazepam; ATC code N05CD, whereas 
z-hypnotics were zopiclone and zolpidem; ATC code N05CF.  
 
The use of anxiolytics in 2004-2007 was identified from NorPD for paper IV; ATC code 
N05B. The anxiolytics used in Norway are three BZDs – diazepam, oxazepam and 
alprazolam – and two non-BZDs – hydroxyzine and buspirone. Users were defined as having 
filled one or more anxiolytic drug prescriptions during 2004-2007.  
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The use of different types of drugs was, for paper III, recorded from health surveys, with the 
following questions and answering alternatives: “How often during the last four weeks have 
you taken (a) anxiolytics (b) hypnotics and/or (c) antidepressants? (1) Daily; (2) Every week, 
but not daily; (3) Less often than every week; (4) Not taken during the last four weeks. 
Individuals who answered 1, 2 or 3 were defined as users. People who had used anxiolytics 
and/or hypnotics were treated together, but if some of these also had used antidepressants, 
they were categorised as antidepressant users instead. People who had used neither of these 
drug categories were defined as non-users.  
 
3.3.2 Independent and/or confounding variables 
The independent variables used in the different papers are shown in Table 5.  
 
Drug use 
Information on drug use as independent variables for papers I, III and IV was collected from 
health surveys. In HUBRO and OPPHED (papers III and IV), the question on use of 
anxiolytics, hypnotics or antidepressants and answering alternatives read “How often during 
the last four weeks have you taken (a) anxiolytics (b) hypnotics and/or (c) antidepressants? (1) 
Daily; (2) Every week, but not daily; (3) Less often than every week; (4) Not taken during the 
last four weeks. Individuals who answered 1, 2 or 3 were defined as users. The questions on 
use of analgesics or other prescription drugs were similar. In Østfold and Aust-Agder (paper 
I), the use of anxiolytics, hypnotics or analgesics during the past month was asked for, with 
the same answering alternatives as in HUBRO and OPPHED; however there were no 
questions on antidepressants or the category “other prescription drugs”.   
 
Users of analgesics were, in papers I and III, defined as people who answered that they had 
used analgesics daily or every week during the previous month. People who used analgesics 
less than every week were defined as non-users according to probable common monthly use 
of analgesics among women because of menstrual pain. The use of analgesics was defined in 
the same way for men. There were separate questions regarding the use of analgesics on 
prescription or over the counter (OTC) in HUBRO and OPPHED (papers III and IV), both 
contributing to the “use of analgesics” variable. In paper IV, individuals who had used OTC 
analgesics less frequently than every week were defined as non-users. In Østfold and Aust-
Agder, there was only one question on analgesic drug use, which did not distinguish between 
prescribed and OTC drugs.  
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Information on drug use as independent variables for paper II was retrieved from NorPD.  
Filled prescriptions two years prior to the participants’ first prescription for hypnotics were 
registered for the following drugs: BZD anxiolytics, antidepressants, antipsychotics and 
lithium, opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and anti-diabetic 
drugs (oral insulin for injection).  
 
 
Table 5 Independent and/or confounding variables used in papers I-IV     
     
Domain Examined Paper number 
    I II III IV 
Drug use (ATC code) Use of anxiolytic drugs (N05B) x x     
  Use of hypnotic drugs (N05C) x    x 
  Use of antidepressants (N06A)  x  x 
  Use of antipsychotics (N05A)  x    
  Use of analgesicsa x x x x 
  Use of other prescribed drugs       x 
Health status HSCL-10 score b    x x 
  Mental distress for which one sought help     x 
  Self-reported health    x x 
  CVD or diabetes symptoms or drugs     x 
  Musculo skeletal pain     x 
  Body mass index x    x 
  Blood pressure x    x 
  Blood test variables x      
  Use of health services other than GP     x 
Lifestyle Smoking x   x x 
  Alcohol consumption x   x x 
  Coffee consumption x      
  Physical activity x   x x 
Demographics Gender  x  x 
  Age  x x   
  Marital status x    x 
  Prescriber's speciality  x    
Socioeconomic factors Educational level     x x 
  Domestic work as main occupation x      
  Receiving sick leave, unemployment benefits,         
  rehabilitation benefits or disability pension c x   x x 
      
a Paper I, III and IV: analgesics in general; prescribed or over the counter     
a Paper II: opioid analgesics (N02A) or NSAIDs (M01A); prescribed only      
b Paper III: HSCL-10 score used in selection; not as independent variable     
c Paper I: not unemployment benefits     
c Paper II: only disability pension     
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Health status 
Information on health status was collected from health surveys for papers I, III and IV.  
 
HSCL-10 score 
Mental distress symptoms measured by HSCL-10 score were used both during selection 
(paper III) and as an independent variable (paper IV) (Table 5). The questionnaires in 
HUBRO and OPPHED included Hopkins symptom checklist-10 (HSCL-10); a screening 
instrument measuring mental distress symptoms in the general population, which is derived 
from the widely used HSCL-25 (108). HSCL measures certain aspects of mental distress by 
symptom questions and has shown good psychometric properties (10).  
 
The 10-item version (HSCL-10) captures symptoms of depression and nervousness during the 
previous week and consists of the following ten items: suddenly scared for no reason; feeling 
fearful; faintness, dizziness, or weakness; feeling tense or keyed up; blaming yourself for 
things; difficulties falling asleep or staying asleep; feeling blue; feeling of worthlessness; 
feeling everything is an effort; feeling hopeless about the future. Each item was rated on a 
scale of 1 (not troubled) to 4 (troubled a lot), and the mean score was used as a measure of 
mental health. Individuals answering fewer than six of the ten questions were given no mean 
score.  
 
In paper III, HSCL-10 score was rather a selection criterion than an independent variable. 
There were two age groups for both sexes, and only the 15% with the highest mean HSCL-10 
score in each group were selected for the study. The cut-off values were for adult women:      
 1.80; elderly women:  1.90; adult men:  1.60; elderly men:  1.60.  
 
In paper IV, participants in each of the two age groups for both sexes were divided into 
quartiles (Q1-Q4) according to their HSCL-10 score at baseline. Baseline characteristics were 
shown for each quartile in each of the two age groups for both sexes. In the multivariate 
analysis, HSCL-10 score quartile was an independent variable, with the lowest quartile as 
referent.  
Mental distress for which one sought help 
The question on mental distress read: “Have you experienced mental distress for which you 
have sought help?” with answering alternatives “yes” and “no” (paper IV).   
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Self-reported health 
Self-reported health was measured by the question: “How would you describe your present 
state of health?” in papers III and IV. The response categories were poor, not very good, good 
and very good; in the analyses they were dichotomised into “good or very good” and “poor or 
not very good”. Similar questions are used and validated elsewhere (136).
 
CVD or diabetes symptoms or drugs 
Participants ticked “yes” or “no” for questions on present or previous myocardial infarction, 
angina pectoris, stroke and diabetes, and were asked to report if they were now using 
medicines because of high blood pressure or cholesterol. From this, two groups were defined 
in paper IV: Those 1) with and 2) without a history of cardiovascular disease (CVD) and 
diabetes or CVD and diabetes drug use. The questions on CVD and diabetes have been 
validated, suggesting that questionnaire information on myocardial infarction is reliable and 
more reliable than similar information on stroke (underreporting) and diabetes (reporting error 
difficult to quantify) (137).  
 
Musculo skeletal pain 
Six potential areas for musculo skeletal pain were listed in the questionnaire. The participants 
reported if they had suffered from pain and/or stiffness in muscles and joints in these areas in 
the course of the last four weeks, by ticking off “very troubled”, “somewhat troubled” or “not 
troubled” in each of the six areas. In the analyses we did not distinguish between “very 
troubled” and “somewhat troubled”, and the number of painful areas was divided into “no”, 
“1-2” or “3-6 painful areas” (paper IV).  
 
Body mass index 
Weight and height were measured at the medical examination, and the Body mass index 
(BMI) was calculated in papers I and IV. The values were dichotomised into BMI < 30 and 
BMI  30 kg/m², which is classified by WHO as obese (138).  
 
Blood pressure 
The medical examination comprised measurements of systolic and diastolic blood pressure. 
Mean values of both systolic and diastolic blood pressures were among the baseline 
characteristics in paper I. In paper IV, the limit between normal and high blood pressure was 
set at > 140/90 mm Hg (48).    
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Blood test variables 
At the medical examination, venous non-fasting blood samples were drawn for measurements 
of serum total cholesterol, glucose and triglycerides to be determined at the Central 
Laboratory of Ullevål Hospital, Oslo (68). Total cholesterol, triglycerides and high-density 
lipoprotein (HDL) were among the baseline characteristics in paper I.  
 
Use of other health services than GP 
This implied the use of a company doctor, psychologist, psychiatrist or other specialist, 
admission to hospital or home nursing service during the last 12 months (paper IV).  
 
 
Lifestyle
Information on lifestyle was collected from health surveys for papers I, III and IV.  
 
Smoking
The questions on smoking habits in the health surveys in Østfold and Aust-Agder (paper I) 
read: “Do you smoke daily at present?” with answering alternatives “yes” and “no”; “How 
many cigarettes do you or did you previously smoke daily? State the number of cigarettes.” 
A different question on smoking in HUBRO and OPPHED (papers III and IV) made it 
possible to separate previous smokers from other current non-smokers. The question read: 
“Have you smoked/do you smoke daily?” with answering alternatives “yes, now”, “yes, 
earlier” and “no”.  
 
Alcohol consumption 
The question on alcohol in Østfold and Aust-Agder (paper I) concerned alcohol consumption 
in the past 14 days, with five possible answering categories, and from this the dichotomous 
variable “teetotaller” versus “others” was made. In HUBRO and OPPHED (papers III and IV) 
alcohol consumption in the past year was asked for by giving eight possible answering 
categories, that was divided into three; “teetotaller”, “up to three times a week” and “4-7 
times a week”.  
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Coffee consumption 
Participants were asked to tick off one category of number of cups of coffee usually drunk per 
day, and from this the dichotomous variable “up to four cups” and “five or more cups of 
coffee/day” was made in paper I.  
 
Physical activity 
Participants in Østfold and Aust-Agder (paper I) were asked to tick off one mean level out of 
four described levels of physical activity in their spare time. Ticking off the less active level 
meant “seldom/never physical active”. In HUBRO and OPPHED (papers III and IV), 
participants were asked to estimate the number of hours per week of a) light exercise and b) 
hard physical activity. Light and/or hard activity less than one hour per week was set as “low 
physical activity”.  
 
 
Demographics 
Information on demographics was collected from health surveys as well as health and 
population registries for papers I-IV.  
 
Age
In paper I, the participants were all of the same age (40-42 years). In paper II, the participants 
were categorised into 10 year age groups; the youngest one (18-29 years) being the referent. 
In paper III and IV, adults and elderly were treated separately: 30/40/45 years and 60 years 
(paper III); 40/45 years and 60 years (paper IV). In paper III, within the adults, the 40/45 year 
old participants were compared to the reference group of those 30 years old.   
 
Marital status 
Information about marital status was retrieved from the National Population Register. In 
paper I, the variable was dichotomised into “married” and “unmarried or formerly married”. 
In paper IV, the variable was dichotomised into “married or in partnership” and “not married, 
widower, divorced or separated”.  
Prescriber’s speciality 
Prescriber’s speciality was retrieved from NorPD, and categorised into: “psychiatry”; “general 
practice”; and “other or no speciality” (paper II).  
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Socioeconomic factors 
Information on socioeconomic factors was collected from health surveys for papers I, III and 
IV.  
 
Educational level 
Numbers of years of education was stated in HUBRO and OPPHED (papers III and IV). The 
variable was dichotomised into “< 13 years” and “ 13 years”, as Norway offers 13 years of 
compulsory education.  
 
Domestic work as main occupation 
The question on domestic work read: “Is domestic work your main occupation?” with 
answering alternatives “yes” and “no” (paper I). 
 
Receiving social benefits 
Participants were asked if they were receiving each of the four social benefits: sick leave, 
unemployment benefits, rehabilitation benefits or disability pension. In paper I, receiving sick 
leave, rehabilitation benefits or disability pension was united into one variable. In paper III, 
all four benefits were aggregated. In paper IV, information on disability pension only was 
used.  
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3.4 Ethics 
3.4.1 Approval of the study 
Data from Østfold and Aust-Agder: The Norwegian Data Inspectorate approved the surveys. 
Written informed consent was introduced in health surveys from 1992; later than the Østfold 
and Aust-Agder health surveys. Participants were informed that the data would be used for 
research purposes, but they were not asked to approve the later record-linkage to the National 
Population Register. This linkage was approved by the Regional Committee for Research 
Ethics, claiming the participants must be allowed to withdraw from the linkage. Participants 
were not contacted individually, but information on planned record-linkage and how to 
withdraw from this was published in the media.   
 
Data from HUBRO and OPPHED: The Norwegian Data Inspectorate approved and the 
Regional Committee for Research Ethics evaluated each study (139). The studies have been 
conducted in full accordance with the World Medical Association Declaration of Helsinki 
(140).  
 
Data from NorPD: The Norwegian Data Inspectorate approved both NorPD and the record-
linkage to health survey data (HUBRO and OPPHED).  
 
3.4.2 Funding and conflict of interest 
This thesis was funded by a research grant from the Norwegian Foundation for Health and 
Rehabilitation and the Norwegian Council for Mental Health. Paper I was also supported by 
the Norwegian Community Pharmacy Foundation. I have received no other funding for this 
work from any commercial sources. Paper IV is a part of the project, “The epidemiology of 
prescription drug use. A record-linkage study in Norway” which is financially supported by 
the Norwegian Research Council. 
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3.5 Statistical methods 
Table 6 summarises statistical packages and methods used.  
 
Table 6  Statistics in papers I-IV     
     
    Paper number 
    I II III IV 
Statistical package SPSS 12.0     x   
  SPSS 14.0 x x   x 
  Stata 9 x       
Statistical methods Chi-square test x x x x 
  F test x      
  Student's t-test   x     
  Multivariate logistic regression   x x x 
  Cox regression x      
  Likelihood ratio test x x   x 
 
 
The statistical analyses were performed using the Statistical Package for the Social Sciences 
Programme (SPSS) version 12.0 (paper III) and version 14.0 (papers I, II and IV), and the 
Stata Release 9 (paper I). Descriptive statistics, univariate, and multivariate analyses were 
performed. All main analyses used dichotomous dependent variables.  
Chi-square or chi-square for trend was used to test differences between proportions for 
categorical variables, whereas Student’s t-test was used for continuous variables. F-test was 
used to assess equality of mean values.  
 
Those variables that reached a significance of p<0.05 in univariate analysis were entered into 
a Cox regression to determine their influence on mortality (paper I) or a multivariate logistic 
regression to determine their influence on drug use (papers II and III). In paper IV, variables 
with a p value <0.25 in univariate analysis were selected for the multivariate logistic 
regressions if considered scientifically relevant. This was done in accordance with Hosmer 
and Lemeshow, explaining that the more traditional level of significance (p<0.05) often fails 
to identify variables known to be important (141). 
 
In paper I, hazard ratios (HRs) were estimated by using the Cox proportional hazard 
regression model. HRs were estimated in several steps: 1) crude HR for men and women daily 
using anxiolytics/hypnotics, 2) adjustment for the use of analgesics and smoking,  
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3) adjustment for some other possible confounders (marital status, coffee drinking, physical 
activity, sick leave and receiving rehabilitation benefit or disability pension) and 4) further 
adjustment including other variables that reached a significance of p<0.05 in the univariate 
analysis. Data from 4) was not shown as this did not substantially change the hazard ratios. 
The proportional hazard assumption was checked by a test based on Schoenfeld residuals, 
using the stphtest procedure in Stata Release 9 (paper I).  
 
Testing for interaction was done by likelihood ratio test in a model with and without the 
interaction term (papers I, II and IV).  
 
Analyses were stratified by gender. However, in papers II and IV only aggregated results 
were presented; with gender as an independent variable.  
 
Testing for interaction was done by likelihood ratio test in a model with and without the 
interaction term:  
 between frequency of drug use and receiving disability pension (paper I)  
 between age and gender (paper II) 
 between HSCL-10 score and gender (paper IV) 
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4.0 SYNOPSIS OF PAPERS 
4.1 Paper I 
Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total 
mortality in a general middle-aged population. Pharmacoepidemiology and Drug Safety 
2007;16:913–918.
Objectives:
The aim of the study was to evaluate the effect of the consumption of anxiolytic or hypnotic 
drugs on total mortality in a general population. 
Material and methods:  
We followed a cohort of 7225 men and 7726 women aged 40-42 years who participated in 
health surveys between 1985-1989 in two Norwegian counties, with respect to deaths. The 
total response rate was 72.0% for men and 80.9% for women. Mean follow-up period was 18 
years. The subjects were categorised according to frequency of anxiolytic or hypnotic drug 
use during the previous month: daily, every week, less than every week, not used during 
previous month. 
Results: 
 The proportion of anxiolytic or hypnotic drug users was 6.6% among men and 16.2% 
among women at baseline, when they were 40-42 years old.  
 Altogether 402 men and 290 women died during follow-up.  
 There was an increasing risk of death with increasing frequency of drug use.   
 Crude hazard ratios (HRs) for daily users of anxiolytics or hypnotics were 3.1 (CI 2.0, 
4.8) for men and 2.7 (CI 1.9, 4.0) for women, as compared with non-users last month.   
 After adjustment for use of analgesics and smoking, the HRs were reduced to 2.4 (CI 
1.5-4.0) for men and 2.1 (CI 1.4 -3.2) for women.  
 After additional adjustment for marital status, coffee drinking, physical activity, sick 
leave and receiving rehabilitation benefit or disability pension; the HRs were further 
attenuated to 1.5 (CI 0.9-2.7) for men and 1.7 (CI 1.1-2.6) for women. 
Conclusions:  
Daily users of anxiolytic or hypnotic drugs in our study showed higher crude mortality than 
non-users. However, after adjustment for lifestyle and socioeconomic variables the difference 
was no longer significant for men and markedly reduced for women, suggesting that the 
remaining excess mortality is due to residual confounding. 
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4.2 Paper II 
Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: 
the use of benzodiazepines versus z-hypnotics. A prescription database study of 
predictors. Eur J Clin Pharmacol 2009;65:295-301. 
 
Objectives:
Drugs prescribed for treatment of insomnia are usually benzodiazepine hypnotics or the newer 
z-hypnotics, zopiclone and zolpidem. This paper explores possible explanations for the choice 
made and gives prevalence and incidence of use.  
Material and methods:  
Data from the Norwegian Prescription Database (2004-2006) covering the entire population 
was studied for incident users of hypnotics in 2006. Incident users were defined as individuals 
filling a prescription in 2006, without any recorded prescription of hypnotics during the 730 
days (2 years) prior to that prescription. Age span studied was 18-69 years. Possible 
predictors for the first hypnotic drug prescribed being a benzodiazepine rather than a z-
hypnotic were age, gender, previous psychotropic or analgesic drug use and prescriber 
speciality. 
Results:  
 In 2006, the prevalence of use of z-hypnotics was 4.8% (male) and 9.0% (female), 
whereas the prevalence of use of benzodiazepine hypnotics was 0.8% (male) and 1.0% 
(female).  
 Of the 73 163 incident users of hypnotics in 2006, 3876 (5.3%) were prescribed 
benzodiazepine hypnotics. This means the majority of 69 287 (94.7%) were prescribed 
z-hypnotics.  
 Incidence rates (number of new users per 1000 inhabitants) increased with age from 
the 18-29 year olds through every 10-year age group to the 60-69 year olds; for z-
hypnotics from 10.4 to 31.0 (male) and from 14.9 to 50.8 (female); for 
benzodiazepines from 0.8 to 2.0 (male) and from 0.5 to 2.4 (female).  
 For z-hypnotics, the incidence rates were markedly higher for females than for males. 
For benzodiazepines, there were only minor gender differences.  
 The strongest predictors for being prescribed benzodiazepine hypnotics rather than z-
hypnotics were previous use of anxiolytics (OR 1.8; CI 1.7-2.0) and male gender (OR 
1.5; CI 1.4-1.6).  
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 Other significant predictors for being prescribed benzodiazepine hypnotics rather than 
z-hypnotics were the use of antipsychotic or opioid drugs, and the prescriber being a 
psychiatrist.  
Conclusions:  
Z-hypnotics were commonly prescribed, and Norwegian drug therapy recommendations also 
suggest a preference for z-hypnotics. The clear predominance of the shorter acting z-
hypnotics may be due to the fact that only longer acting benzodiazepines are available in 
Norway. Reasons for prescribing benzodiazepines rather than z-hypnotics may be co-existing 
psychiatric illness, such as anxiety, or a belief that benzodiazepine hypnotics are more 
effective than z-hypnotics. 
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4.3 Paper III   
Hausken AM, Skurtveit S, Rosvold EO, Bramness, JG, Furu K. Psychotropic drug use 
among persons with mental distress symptoms: A population-based study in Norway. 
Scand J Public Health 2007;35:356-364. 
Objectives:
To explore psychotropic drug use in the general population and in particular among non-
institutionalised individuals with mental distress symptoms.  
Material and methods:  
A total of 14 139 women and 11 665 men participating in the Oslo Health Study or the 
Oppland/Hedmark Study 2000-2001 submitted a self-administered questionnaire on health 
status and drug use, lifestyle and socioeconomic factors. The total response rate was 48.5%. 
Respondents answering they had used anxiolytics, hypnotics and/or antidepressants during the 
last four weeks were defined as users. A high Hopkins symptom checklist-10 (HSCL-10) 
score indicated mental distress. The 15% with the highest score in each gender and age group 
(adults: 30/40/45 years; elderly: 60 years) were studied in detail.  
Results: 
 The prevalence of anxiolytic/hypnotic drug use in the general population was, for 
women: adults 5%; elderly 20%; and for men: adults 4%; elderly 9%.  
 The prevalence of anxiolytic/hypnotic drug use among those with mental distress was, 
for women: adults 14%; elderly 37%; and for men: adults 13%; elderly 25%. Except 
for elderly women, these figures were approximately three times higher than in the 
general population.  
 The prevalence of antidepressant use among those with mental distress was, for 
women: adults 21%; elderly 30%; and for men: adults 15%; elderly 15%. These 
figures were nearly four times higher than in the general population.  
 Use of analgesics was the main factor associated with use of anxiolytics/hypnotics 
among people with mental distress: Adult women (OR 2.4; CI 1.7-3.4); elderly 
women (OR 2.3; CI 1.4-3.8); adult men (OR 2.1; CI 1.3-3.3) and elderly men (OR 3.4; 
CI 1.9-6.0). Not participating in the labour market was the main factor associated with 
use of antidepressants.
Conclusions:  
Among individuals with mental distress, regular use of analgesics was the main factor 
associated with use of anxiolytics/hypnotics in both genders regardless of age.
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4.4 Paper IV  
Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of 
anxiolytic drugs – a prospective population-based cohort study of 16 000 individuals. 
Scand J Public Health 2010; June 3, Epub ahead of print. 
 
Objectives:
To study the relationship between mental distress and later use of anxiolytic drugs, taking into 
account potential confounders such as lifestyle and socioeconomic factors.  
Material and methods:  
In a prospective cohort study, data from population-based health surveys from three 
Norwegian counties (2000-2001) were linked to data from the Norwegian Prescription 
Database (2004-2007). In the surveys, 9 386 men (43.1% of invited) and 11 244 women 
(52.4%) participated. The two age cohorts were 40 and 45 years old (cohort 1) and 60 years 
old (cohort 2). Participants in each age group were divided into quartiles (Q1-Q4) separately 
for men and women according to the degree of mental distress, measured by increasing 
Hopkins symptom checklist-10 (HSCL-10) score at baseline. Multivariate logistic regression 
was performed to assess predictors of anxiolytic drug use.  
Results:
 At baseline, increasing HSCL-10 score was associated with increasing use of specified 
drugs independently (hypnotics, antidepressants, analgesics with or without 
prescription, others), poor health, ever having sought help because of mental distress, 
musculo skeletal pain, being married or in partnership, low educational level, 
receiving disability pension, and current smoking (except for women 60 years old).  
 There was a graded positive relationship between HSCL-10 score at baseline (2000-
2001) and the chance of filling a prescription on anxiolytic drugs during follow-up 
(2004-2007) for the 40 and 45 year olds, but not for the 60 year olds. Genders were 
studied together.  
 Predictors of use of anxiolytics, regardless of age, were: female gender, reported use 
of hypnotics, having previously sought help because of mental distress, and current 
smoking.  
Conclusions:
HSCL-10 score was related to later use of anxiolytic drugs in a dose response manner for the 
40 and 45 year olds.  
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5.0 DISCUSSION 
5.1 Discussion of the major findings 
The data analyses in this thesis have resulted in six major findings, listed below.  
 
 Daily users of anxiolytics or hypnotics show higher crude mortality than non-users; 
however after adjustment the difference was markedly reduced.  
 The majority of incident users of hypnotics receive prescriptions for z-hypnotics rather 
than benzodiazepines, the choice of benzodiazepines predicted most strongly by 
previous use of anxiolytics and male gender.  
 The main factor associated with use of anxiolytics or hypnotics among people with 
mental distress is the use of analgesics. 
 The main factor associated with use of antidepressants among people with mental 
distress is not participating in the labour market.  
 Mental distress is a predictor of later use of anxiolytic drugs.  
 Women show a higher proportion of use of psychotropic drugs than men, and there are 
also gender differences when studying mortality and incidence rates.   
 
To obtain information on and read discussion of further findings, the discussion section of 
each paper is recommended.  
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5.1.1 Daily users of anxiolytics or hypnotics show higher crude mortality 
than non-users 
Crude hazard ratios for daily users of anxiolytics and/or hypnotics in a middle-aged 
population (40-42 years) were 3.1 for men and 2.7 for women, as compared with non-users 
last month. Two adjustment models both attenuated the hazard ratios; the first one including  
use of analgesics and smoking, whereas the further adjustment included marital status, coffee 
drinking, physical activity, sick leave and receiving rehabilitation benefit or disability 
pension. The model including all variables gave hazard ratios of 1.5 (ns) (men) and 1.7 
(women).  
 
Earlier findings in this field vary; some authors have found increased all-cause mortality after 
use of benzodiazepines (BZDs) (78-80, 83-86), whereas other have not (77, 81, 82). In the 
study by Hublin et al, increased mortality was found for frequent users of tranquillizers and/or 
hypnotics in a population with an age range of 24-101 years (78). There, the effect attenuated 
with age, something also observed in a study of sleeping pill use and mortality (79). The three 
studies that did not find increased mortality covered the populations of the highest age (77, 
81, 82), and age may be part of the explanation of the various findings.  
 
We have identified ten prospective cohort studies examining the association of BZD use and 
mortality. All studies were from high-income countries within Europe and North America. 
The findings varied, and there are some possible reasons for this, other than age variations. 
Firstly, the definition of use of BZDs in the general population varied as follows: “daily use in 
past month” (as used in paper I); “use sometimes or more often”; “use often or very often”; 
“use at least 60 days per year” “use more than half of the 3 month assessment period”; 
“current use”. In addition, one study covered drug misusers in treatment centres with a 
definition of BZD use as “weekly or more frequent use” (84); one study covered BZD 
dependent users with no further definition of use , and two studies were of drugged drivers 
(85, 86). Secondly, the number of BZDs included in the studies varied and some studies were 
not restricted to BZDs, as either the sleeping pills included were not specified (79) or 
tranquillisers in general were studied, meaning that antipsychotics were included (78). The 
study populations covered different ages as mentioned above; they had varying sizes (nmin = 
599; nmax = 1 099 830; paper I: 14 951), and were followed up for different lengths of time (5-
22 years; paper I: 18 years). Our study like most other studies relied on information about 
BZD use given from participants, and this probably captured prescribed BZDs. On the other 
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hand one study focused on non-prescribed BZDs, according to information from drug 
misusers recruited to treatment programmes (84), and this may also have been the case for the 
studies of BZD dependents or drugged drivers (83, 85, 86).  
 
Regarding data analysis, stratification was either done, like in our study, by frequency of use, 
or by number and/or type of BZDs. Most studies calculated all-cause mortality and presented 
adjusted hazard ratio (HR) (like paper I), relative risk (RR) or odds ratio (OR), whereas one 
study calculated standardized mortality ratio (SMR) (79) and another study compared all-
cause mortality of users versus non-users in percent (77). Our study was one of four which 
controlled for several confounding factors (78, 80, 82), whereas others adjusted for age and/or 
sex only.  
 
We found a dose-response relationship for frequency of use of BZDs and mortality, supported 
by previous findings (78, 79). Other studies did not categorise the users according to 
frequency of use, but in Norway, a group of drivers who tested positive for a single traffic-
hazardous medicinal drug (BZDs, opioids, muscle relaxants) showed SMR 9.8 (men) and 19.6 
(women), changing to 16.9 (men) and 18.4 (women) for the group who tested positive for two 
or more of the drugs (85). 
 
The review by Charlson et al pointed at limitations in the design and data of six studies on 
BZD use and mortality, including our paper I (142). The authors raise two crucial questions 
about the cohort design. 1) Among those who died, how many continued to use sleeping pills 
in the follow-up period? 2) Among those who survived, how many initiated use of sleeping 
pills during the follow-up period? Perhaps the only proper solution to this problem is to 
measure drug use several times during follow-up. One suggested study design could be 
similar to a design used to measure long-term use of BZDs (98), with death as an endpoint.  
 
Findings from two studies illustrate the importance of studying different BZDs separately in 
order to discover differing risks associated with individual drugs. Rumble and Morgan did not 
find an increased risk of mortality among hypnotic drug users (81). However, an initial 
association was found between increased mortality and the use of sleep medication, but once 
this category was broken down into hypnotic drugs (mainly BZDs) and other sleep 
medication, only the “other” category remained significantly associated with increased 
mortality. Similarly, Kripke et al showed an association between sleeping pill use and an 
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increased risk of death (79), however the sleeping pills included were not specified – and 
were thus not restricted to BZDs. Separate analyses of diazepam and chlordiazepoxide, 
respectively, did not reveal increased mortality associated with these particular drugs. 
 
BZDs are psychoactive drugs and are more often used by people who suffer from co-
morbidity; somatic or psychological (106). Perhaps BZDs are merely a proxy for other risk 
factors associated with increased mortality. If there is, in fact, an increased mortality risk, it is 
not known whether this risk is carried by certain “at risk” populations who may have 
coexisting risk factors. In Norway, Mykletun et al recently studied associations between 
individual and combined anxiety/depression symptom loads, using the Hospital Anxiety and 
Depression Scale (HADS), and mortality in the county Nord-Trøndelag (143). Depression as 
a risk factor for mortality was comparable in strength to smoking, whereas co-morbid anxiety 
reduced mortality compared with depression alone. The relationship between anxiety 
symptoms and mortality was more complex with a U-shape and the highest mortality in those 
with the lowest anxiety symptom loads. 
 
Only randomized controlled trials (RCTs) can control for the complexity of confounding 
factors to provide evidence of cause and effect. In paper I, we excluded individuals suffering 
from, or with symptoms indicating, heart infarction, angina pectoris, diabetes and stroke; in 
order to start out with a fairly healthy population. This exclusion may have resulted in lower 
hazard ratios compared to studies without such exclusions. However, among the participants 
there were both disability pensioners (2.2% of the men and 4.4% of the women) and people 
on sick leave or receiving rehabilitation benefit (3.0% of the men and 5.5% of the women); 
indicating some health problems. Further, during a follow-up period of 18 years the health 
status of participants 40-42 years old at baseline probably goes through greater changes than 
before selection, and therefore our study is still affected by coexisting risk factors. Kripke in 
fact suggested RCT as a requirement for those who introduce or approve new hypnotics 
(144). 
 
Even after doing a study on psychotropic drug use and mortality, I find the field complex 
because of the varying methods used and the sometimes conflicting findings published. From 
our findings, I find it hard to conclude that there is a clinically relevant association between 
daily use of anxiolytics and hypnotics and increased total mortality.  
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5.1.2 The majority of incident users of hypnotics receive z-hypnotics 
rather than benzodiazepines 
Most incident users of hypnotics in Norway in 2006 were prescribed z-hypnotics (94.7%) and 
only 5.3% were prescribed BZD hypnotics. I know of no similar studies. However, all the 
Nordic countries have established nationwide prescription databases making it possible to 
perform studies like paper II (71). 
 
In our study, incidence rates (number of new users per 1000 inhabitants) for BZD hypnotics 
and z-hypnotics separately increased with age for both genders. Incidence rates were higher 
for women than for men, except for the younger BZD users. Two recent studies have looked 
at the total incidence of BZD anxiolytics, BZD hypnotics and z-hypnotics in France (94) and 
Taiwan (91). These aggregated incidence rates are less relevant to compare with our findings. 
The gender difference we found was also observed in France, whereas results for women and 
men separately were not given in the study from Taiwan.  
 
Predictors for being prescribed BZD hypnotics rather than z-hypnotics among incident users 
in our study were male gender, previous use of anxiolytics, antipsychotics or opioid 
analgesics and the prescribing doctor being a psychiatrist. A study on the use of BZDs and z-
hypnotics was carried out by Johnell and Fastbom using the Swedish Prescribed Drug 
Register (92). In Sweden, all current users were included, and the use of BZDs with medium 
acting time was associated with higher age, female gender, and concomitant use of other 
psychotropics, whereas z-hypnotics showed the opposite patterns. Interestingly, zopiclone and 
zolpidem showed different patterns regarding age, sex and concomitant use of other drugs, 
and Johnell and Fastbom emphasize the importance of examining the use of individual drugs 
instead of clustering them into drug classes. Further, they found that the two long-acting 
BZDs, flunitrazepam and diazepam, showed divergent patterns of use. Among the BZDs, we 
studied the hypnotics nitrazepam and flunitrazepam only, whereas Johnell and Fastbom 
studied several BZDs and categorised them according to their acting time. Their group of 
“long-acting” included the drugs we studied, nitrazepam and flunitrazepam; but was 
completed by the inclusion of clonazepam and diazepam. The Swedish study was restricted to 
people  75 years (mean age 82 years), in contrast to the age range of 18-69 years in our 
study; meaning that prevalence of use among Norwegians in our study is irrelevant to 
compare with the Swedish findings. Our measured prevalence of hypnotic drugs in 2006 was 
comparable to other prevalence findings from Norway. The prevalence we found for BZD 
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hypnotics (male: 4,8%; female: 9.0%) and z-hypnotics (male: 0.8%; female: 1.0%), added up 
to 8% whereas Kjosavik et al reported 7.9% from NorPD in 2005 and Pallesen et al found 
6.9% from telephone interviews a few years earlier (88, 89).  
 
In a French cohort of 1272 subjects aged 59-71 years, incident BZD or z-hypnotic drug use 
was associated with anxious and/or depressive symptoms, high non-psychotropic drug 
consumption and female gender (94). As BZD anxiolytics, BZD hypnotics and z-hypnotics 
were studied together, comparisons with our study are difficult to make.  
 
Bachmann et al (59) suggested a possible lack of knowledge on sleep and hypnotics in 
general in a study among Norwegian general practitioners (GPs), and was supported in a 
comment by Bjørner (63). Norwegian GPs with a high level knowledge of clinical use and a 
restrictive attitude to z-hypnotics showed a lower prescription rate for BZDs and z-hypnotics, 
and the arguments for choosing zopiclone instead of zolpidem or vice versa were often 
irrational (59). Regarding GPs’ knowledge, Siriwardena et al found that GPs in Lincolnshire, 
UK, believed that z-hypnotics were more effective and safer than BZDs (62). This may 
explain the increase in z-hypnotics drug prescribing relative to BZD prescribing in the UK, 
but was not in agreement with current evidence or national guidance.  
 
Paper II showed that in Norway in 2006, 3876 incident users of hypnotics were prescribed 
BZD hypnotics (5.3%). This may or may not be too worrying, depending whether one 
believes z-hypnotics to be a clearly better option than BZD for every incident hypnotic drug 
user or whether it is just another contribution to the stories of promising new drugs marketed, 
with rapidly rising levels of sales; at least until all possible consequences of their use are fully 
discovered.  
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5.1.3 The main factor associated with use of anxiolytics or hypnotics 
among individuals with mental distress is use of analgesics 
The main factor associated with use of anxiolytics or hypnotics among individuals with 
mental distress was use of analgesics (paper III), confirming the findings published by 
Villaverde Ruiz et al (107).  
 
Further, we found in paper III a prevalence of anxiolytic or hypnotic drug use approximately 
three times higher for the 15% with the highest Hopkins symptom checklist-10 (HSCL-10) 
score on mental distress than for the general population; except for elderly women. In order to 
compare our findings with earlier studies, it is relevant to add the prevalence of 
antidepressants to these numbers. Among responders with mental distress, the prevalence of 
psychotropic drugs then added up to 31% (men) and 43% (women), not far from the higher 
level of previous findings (101). In paper IV, at baseline, increasing HSCL-10 score was 
associated with increasing use of hypnotics and antidepressants. This population was part of 
the population in the cross-sectional study in paper III, explaining similar findings at baseline. 
Follow-up (paper II) showed that mental distress was found to be related to later use of 
anxiolytic drugs in a dose response manner among middle-aged people. Among the older 
people, use of hypnotics was the most important predictor of anxiolytic drug use.  
The boundaries between anxiolytics and hypnotics can be unclear, and among the older 
people we may have observed change of drug prescribed for the same indication, rather than 
the use of one drug predicting the use of another.  
 
It might be a paradox that people receiving medical treatment for mental health distress or 
perhaps diagnosed mental disorder may not have a normal score on mental distress even if the 
treatment is successful. From another point of view, they perhaps would have scored even 
higher without medical treatment. Further, an important issue is whether the medical 
treatment has recently started or lasted for years. Finally, a large proportion of people with 
mental distress in our study were actually not taking psychotropic drugs; 44-73%, varying 
with gender and age.  
Cloos and Ferreira provide a review of articles on the current use and rationale of BZDs in 
anxiety disorders (145). BZDs are considered by many clinicians to remain good treatment 
options, in both the acute and the chronic phase of the treatment of anxiety disorder, partially 
because of their rapid onset of action and their efficacy with a favourable side effect profile. A 
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qualitative study by Anthierens et al on GPs’ perspectives showed that clinicians feel 
overwhelmed by the psychosocial problems of their patients and considered themselves to be 
empathic by giving them BZDs as a relief (58). Given the lack of adequate alternatives and 
because of limited time, it was felt that in certain situations there are no other solutions and 
BZDs were perceived as the “lesser evil”. The addictive nature of BZDs was not considered 
to be a problem with first-time users, and the GPs thought that under-usage of BZDs because 
of a fear of addiction may leave patients suffering. This study is an example of BZD 
prescribing practices not always reflecting guidelines - as these guidelines perhaps do not 
provide the practical strategies required in a complex clinical setting. Sim et al propose a 
model for rational prescribing of BZDs, by the use of a checklist (56). The critical question is 
why the person is using a BZD, i.e. what benefits (perceived or real) are there? How will the 
person who ceases them manage the loss of those benefits?  
 
Smolders et al compared GPs’ pharmacological treatment patterns for anxiety in patients with 
and without co-morbidity (104). Compared with patients with a single diagnosis of anxiety, 
anxious patients who also had chronic somatic morbidity or social problems were prescribed 
more BZDs, but no more antidepressants. When they simultaneously had other psychiatric 
conditions, they received twice as many BZDs and antidepressants during the year after 
anxiety was diagnosed.  
 
Co-morbidity and co-medication are complex fields, and in the future pharmacists may play a 
more important role to patients filling prescriptions for one or more psychotropic drugs as 
well as analgesics. Pharmacists in Norwegian community pharmacies have so far not been 
paid specifically for drug use review one-to-one conversations with a patient. In Australia, 
New Zealand and the UK this is the case (146). If such services are to be paid by the health 
authorities, it is most likely that reimbursed drugs will be given priority, presuming an 
economic motivation. However, from a patient’s view it is not an obvious choice to exclude 
psychotropic drug users from receiving extended pharmaceutical assistance.  
 
Patients may have symptoms of more than one mental disorder, as anxiousness, depression 
and insomnia can partly overlap; and the choice of drug is probably not always easy to make. 
Kripke analysed RCTs on insomnia patients, and found a greater incidence of depression 
among subjects receiving hypnotics versus those receiving placebo – suggesting hypnotics 
may be more likely to cause depression than to prevent it (147).  
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5.1.4 The main factor associated with antidepressant use among 
individuals with mental distress is to be out of the labour market 
We found in paper III that among individuals with mental distress, not participating in the 
labour market was the main factor associated with use of antidepressants. In paper IV, the 
working status variable was restricted to receiving disability pension (yes/no), and predicted 
the use of anxiolytics for those aged 40/45 years only (OR 1.4). Further, in paper III, not 
participating in the labour market was the main factor associated with use of anxiolytics or 
hypnotics for adult men, and one of the factors associated with use for both adult and elderly 
women. 
 
In paper III, the separate statements of main factors associated with anxiolytics/hypnotics or 
antidepressants, respectively, can be criticized because of the way psychotropic drug users 
were classified. People who had used antidepressants were defined as antidepressant users, 
regardless of their possible use of anxiolytics or hypnotics. Remaining in the group of 
anxiolytic or hypnotic drug users were those not using antidepressants. Even if we focus on 
anxiolytic and hypnotic drug users in this thesis, we treated antidepressant users as more 
unique in paper III, simply because receiving a prescription of 10 or 30 tablets of 
antidepressants is not as common as is the case with anxiolytics and hypnotics. Further, 
analyses of people using antidepressants exclusively (n=240) showed that they did not differ 
from the previously defined group of antidepressant users (n=648).  
 
In a Norwegian study, Hartz et al found that receiving disability pension was associated with 
the use of BZDs 20 years later (148). Another study by Hartz et al stated that the chance of 
being prescribed a BZD as well as becoming a long-term user was higher among disability 
pensioners (149). Smolders et al found that anxious patients who also had social problems; 
defined as bad working conditions, unemployment, relation problems or grief, were 
prescribed more BZDs (104). A different finding was done by Verger et al who studied co-
prescriptions of antidepressants and anxiolytics, and found that 60% of patients receiving 
antidepressants were also prescribed an anxiolytic (108). GPs co-prescribed anxiolytics more 
often for patients with stable jobs than for those with unstable or no jobs or those who were 
retired. The authors hypothesize that patients with regular jobs might demand more 
symptomatic relief than patients in other situations and GPs might consider anxiety and sleep 
problems as target symptoms in these patients, compared with unemployed patients. The 
potential for abuse might be another reason why GPs were less likely to prescribe anxiolytics 
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to unemployed patients, suggesting the possibility of a stigma of unemployment. Noticeably, 
Verger et al studied patients with major depressive disease only, while in paper III we studied 
those with the 15% highest HSCL-10 score in the general population; and used no diagnostic 
cut-off.  
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5.1.5 Mental distress is a predictor of later use of anxiolytic drugs
Mental distress measured by HSCL-10 score was found to be related to later use of anxiolytic 
drugs in a dose response manner among middle-aged people. Perhaps more surprising was the 
fact that among those 60 years old, the dose response relationship disappeared. Others have 
done cross-sectional population-based studies and measured mental distress in other ways, 
and have found the presence of a mood or anxiety disorder to be strongly associated with the 
use of BZDs or z-hypnotics (93, 102).   
We found in paper IV that previous help seeking for mental distress predicted anxiolytic drug 
use. Similarly, the European study of the epidemiology of mental disorders (ESEMeD) found 
help seeking for emotional problems in the previous year to be the most important predictor 
for the use of a BZD or an antidepressant (101). Tómasson et al found that among those 
consulting a doctor in Iceland during the previous 12 months (57%), the most important factor 
associated with use of any psychotropic drugs was having consulted a doctor for mental 
health problems (105).  In the multivariate analyses, we included reported help seeking for 
mental distress as a confounder. This can be questioned as the search for help was not 
restricted to any time period.  
Mental health status was in our study measured by HSCL-10, derived from the HSCL-25 
(16). HSCL measures certain aspects of mental distress and has shown good psychometric 
properties (10). A validation study has demonstrated a high correlation between the HSCL-25 
and the HSCL-10 (16). However, this instrument is a screening tool, and not a diagnostic 
instrument. Further, our measure of health status using HSCL-10 did not include a diagnosis-
related cut-off. In paper III, we chose to study people with the 15% highest HSCL-10 score. 
This decision was not related to the HSCL-10 score cut-off value of  1.85 known to indicate 
mental distress, and when we included as many as 15% of the participants, people with scores 
far below 1.85 had to be included. Initially, we considered using the cut-off value of  1.85. 
However, women score higher than men without our knowing whether they in fact have more 
mental distress than men or if they “complain” more. Sandanger et al studied to what extent 
the symptom screening HSCL-25 predicted depressive disorders found by the diagnostic 
instrument Composite international diagnostic interview (CIDI), and suggested lower HSCL-
25 score cut-off for men than for women (15). I presume it is possible that women “complain” 
more than men also during CIDI, and CIDI should perhaps not be regarded as a true measure 
of mental health status either. Sandanger et al in a later study were actually surprised by the 
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different properties HSCL-25 and CIDI showed when identifying cases (150). Choosing a 
certain highest percentage of each gender was our method of selecting similar groups. In 
paper IV, participants were divided into HSCL-10 score quartiles. The quartiles were gender 
specific for the same reason as we left the cut-off value.  
 
Noticeably, the time frames assessing HSCL-10 score (last week), drug use (last month), and 
use of health services (up to 12 months) were different. This may complicate the 
interpretation of the associations, as the variables may change over time. In paper IV, among 
the dead who were excluded, there was a higher proportion that would have belonged to the 
quartile with the highest HSCL-10 score. This may have led to an underestimation of the 
effect of a high HSCL-10 score.  
Among people with mental distress in the non-institutionalized population, we found that 
31% of the men and 43% of the women used any psychotropic drug. Rundberg et al found 
that a lower proportion of 15% of women aged 50-59 with severe mental symptoms used 
psychotropic drugs (23). Noticeably, we studied the 15% with the highest HSCL-10 score, 
whereas Rundberg et al studied 22% of the participating women; those with severe mental 
distress as defined by the Gothenburg quality of life instrument (GQL) (13, 23). None of the 
studies used a diagnosis-related cut-off. However, we studied a slightly more homogenous 
group. The larger proportion of a general population included, the more people with lower 
levels of mental distress will presumably be represented. Further, our study included as users 
all those who had used psychotropic drugs during the previous month, whereas Rundberg et al 
included regular users only (23). The higher percentage of psychotropic drug use found in our 
study was thus not unexpected.  
 
Mental distress can be measured not only by instruments like HSCL-10 score, as receiving a 
prescription of antidepressant drugs can be a proxy of depression. A Swedish study of 
previous and later use of BZDs among new antidepressant users can illustrate the indistinct 
boundary between the psychotropic drugs studied in this thesis and possible co-morbidity of 
depression and anxiety. Bingefors et al suggest there may be widespread treatment of 
depressive symptoms with BZDs, as new antidepressant users had an increasing and high use 
of BZDs compared to non-users in the year prior to their first antidepressant prescription 
(151). The BZD use remained high throughout the study period of five years.  
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5.1.6 Women show a higher proportion of use of psychotropic drugs 
than men 
We observed gender differences in mortality, prevalence and incidence rates. Women showed 
a higher proportion of use than men, and this counted for all drug groups: anxiolytics, BZD 
hypnotics, z-hypnotics and antidepressants (papers I, II, III and IV). This is in concordance 
with other studies (24, 93, 101). Among users of anxiolytics or hypnotics, only women 
showed higher mortality after adjustment for lifestyle and socioeconomic variables (paper I). 
From this, one may conclude that women using these drugs have poorer health than men 
using the same drugs, and that the health is poorer in a way that increases mortality. Further, 
men (non-users and users together) showed a higher mortality than women (non-users and 
users together), and thus the minor increase from taking drugs was perhaps not enough to 
significantly increase mortality for men. Hypnotic drug incidence rates were higher for 
women than men for z-hypnotics, whereas for BZD hypnotics there were only minor gender 
differences (paper II). Male gender was one of the strongest predictors for being prescribed 
BZD hypnotics rather than z-hypnotics (paper II). BZD is more attractive to drug misusers 
than z-hypnotics, and as more men than women are misusers this may contribute to the gender 
difference. 
 
Among people with mental distress, the prevalence of anxiolytic or hypnotic drug use was 
similar for men (13%) and women (14%) (paper III). In contrast to this, Marino found that 
when men scored above the threshold of psychiatric morbidity in the General health 
questionnaire (GHQ-30) they had a risk of receiving a psychotropic drug 49 times higher than 
the general sample, whereas women had no significant increase of risk (117). Marino suggest 
that a greater weight is given by the GPs to distress symptoms exhibited by men compared to 
women and that in the presence of these manifestations a more serious clinical problem is 
assumed, leading to the prescription of a psychotropic drug.  
 
Further, among people with mental distress, the ORs of later filling prescriptions of 
anxiolytics were comparable for the two sexes within age groups (paper IV). Women scored 
higher than men on HSCL-10. We are not sure whether women in fact had more mental 
distress or if they were using the scale differently from men, when rating themselves from 1 
to 4 on each of the 10 symptom questions. This has previously been discussed in the section 
“Mental distress is a predictor of later use of anxiolytic drugs” of this thesis.  
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Moving from a relative level to an absolute level can give further information on gender 
differences, as similar HRs or ORs can have different practical implications. In paper I, the 
mortality among daily users was 912 for men and 505 for women per 100 000 person years 
(paper I; table 2). Despite this difference, hazard ratios for men and women were similar. In 
paper IV, the level of use of anxiolytics among women is almost twice that for men in each 
HSCL-10 score quartile (Paper IV; tables 3a and 3b). In that study, odds ratios for men and 
women were quite similar for the two genders and only results from men and women 
combined are presented. The adjusted OR for gender were above one for both age groups and, 
as men were used as the reference, this means being a woman was a predictor of anxiolytic 
drug use. The actual size of OR for both age groups was 1.7 and this illustrates the different 
level of the absolute numbers of users among men and women (paper IV; table 4).  
 
The Australian researchers Hollingworth and Siskind point out that women have a higher 
prevalence of anxiety and sleeping disorders, but that it is unclear whether this accounts for 
all of the additional psychotropic drug use they found among women compared to men (152). 
In a Swedish questionnaire-based study of analgesic drug use, women reported pain more 
often than men (153). However, this did not explain the whole gender difference, and the 
author presumes biological as well as environmental and psychological causes are involved 
(153).   
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5.2 Methodological strengths and limitations
NorPD is a nationwide prescription database, with detailed information on patient, dispensed 
drug, prescriber and pharmacy (1). Compared to studying, for example, selected hospital, GP 
or pharmacy records, NorPD data are, for many purposes, superior. Health surveys in 
Norwegian counties are also comprehensive, giving information on health, lifestyle and 
socioeconomic variables. Despite the collection of huge amounts of data from large 
populations, there are methodological challenges that require consideration.   
 
The validity of a study is usually separated into two components: the validity of the inferences 
drawn as they pertain to the members of the source population (internal validity) and the 
validity of the inferences as they pertain to the people outside that population (external 
validity or generalizability) (154) 
 
There are two kinds of error in research: systematic error and random error. Systematic error 
alter estimation in a given direction. Random error is the error that remains after systematic 
error is eliminated. Most violations of internal validity can be classified into three general 
categories of systematic error: selection bias, information bias or confounding (154, 155), 
described in the following sections.  
 
5.2.1 Selection bias 
Selection bias is systematic error that results from the way subjects are selected into the study 
or because there are selective losses of subjects before data analysis (156). It is difficult to 
determine the magnitude of selection bias, but the direction of the bias may be indicated. In 
the health surveys used in this thesis, there were no other selection criteria besides age. Thus, 
the main source of selection bias in the papers using data from health surveys (I, III and IV) is 
non-response, either non-attendance to the screening, or non-response to the questionnaires or 
to single items in the questionnaire. Statements about bias due to non-response are therefore 
statements about defined variables.  
 
Our studies from Oslo, Oppland and Hedmark (papers III and IV) had a lower response rate 
than the study from Østfold and Aust-Agder (paper I). Research has shown that in the Oslo 
Health Study (HUBRO), there was overrepresentation of less educated people and receivers 
of disability pension among the non-attendees (157). Further, disability pension may be used 
as an indicator of poor or reduced health: either physical or mental. This implies that the 
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participants were healthier than the general population. The differences regarding education, 
disability pension and health will not necessarily affect the associations studied. In paper IV, 
the lower attendance of disability pensioners is a possible sign of more mental distress among 
non-attendees. However, if there is an identical attendance percentage of drug users and non-
users among people with and without mental distress, OR will not be biased (158). Further, 
the prospective study design in paper IV probably makes selection bias less likely to influence 
the estimates of the effects of HSCL-10 score on subsequent anxiolytic use (158).  
 
The attendance in HUBRO increased from 30% to 46% through reminders, and the effect of 
this was studied (159). Small changes were observed among the 75-76 years old for the 
estimated prevalence figures of diabetes, poor self-reported health, HSCL-10 score and daily 
smoking. Among individuals of ages included in our study, almost no changes were observed. 
We do not have any information about the non-participants in the studies from Oppland and 
Hedmark (OPPHED), that together with Oslo form papers III and IV, or from Østfold and 
Aust-Agder (paper I). 
 
After publishing paper IV, I compared the prevalence of use of anxiolytics in 2005 for 
participants in the health surveys HUBRO and OPPHED to the corresponding prevalence for 
all inhabitants in the counties of Oslo and Oppland/Hedmark as they were all invited. Table 7 
shows that the prevalence for the health survey participants is from 1.5 to 2.8 percentage 
points lower than for the whole county/counties. This means that among the participants 
available to our study – before the exclusion of e.g. users of anxiolytics at baseline – a smaller 
proportion used anxiolytics during one randomly selected year of the follow-up period, 
compared to the general population. This may reduce the external validity, while the 
associations studied are less likely to be altered.  
 
Increasing the response rate will not necessarily make a population more representative (160). 
In the study of Bootsma-van der Wiel et al, the response rate increased from 74 to 87% by an 
additional recruitment, and the population added had poorer health. However, those who 
refused to participate during the additional recruitment were healthier than the population first 
sampled. In the end, the first sample did not differ from the source population with respect to 
health, sociodemographic factors and mortality. The authors concluded that given a 
moderately high direct response, an additional effort to prevent selection bias is not necessary.  
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Table 7 Prevalence of use of anxiolytics (ATC code N05B) for participants in health surveys in the counties of  
Oslo (HUBRO), Oppland and Hedmark (OPPHED) and for all inhabitants in the counties; they were all invited. 
Source: NorPD 2005 
County/counties Oslo Oppland/Hedmark  
Age* 40/45 60 40/45 60  
   Men - prevalence of use          
Health survey participants (%) 4.9 6.5 3.8 7.0  
The whole county/counties (%) 6.8 8.7 6.0 8.5  
   Women - prevalence of use          
Health survey participants (%) 7.3 13.5 7.6 13.5  
The whole county/counties (%) 10.1 16.1 9.5 15.7  
*Age at health survey selection in 2000-2001.     
 
 
The response rates in our studied counties are different (min = Oslo, 46%, max = Østfold, 
77%), meaning the consequences of increased response would perhaps differ. Further, in 
paper I, non-response would probably affect the prevalence estimates of BZD use at baseline. 
However it is less likely that the association between the frequency of drug use and total 
mortality is affected.  
 
In cross-sectional studies, the primary source of selection bias is “selective survival”, as only 
survivors can be included in cross-sectional studies (156). Prevalent users are “survivors” of 
the early period of pharmacotherapy, which can introduce bias if risk varies with time, 
similarly to studies of operative procedures that follow patients after they have survived 
surgery (161). In paper III, people with mental distress who were prevalent users of 
anxiolytics or hypnotics were “survivors”, in contrast to those having stopped using the drugs 
before baseline for reasons like decreased mental distress or experienced side effects. The 
consequence of this can be seen by pulling the baseline one step backwards. Including people 
who will later stop using the drugs will firstly result in a higher prevalence of use, and 
secondly associations may be altered if the quitters are different from other non-users.  
 
When data were retrieved from NorPD (paper II and part of data for paper IV), selection bias 
was eliminated. However, data on the use of medicines in the hospital and nursing homes are 
not registered on an individual level in the database. For the substances we studied in paper II, 
these omissions account for 8% of total sales in Norway. In paper IV the highest age group 
included in the study is 60 years. This would suggest a rather smaller loss of drug use data 
caused by hospital and nursing home stays compared to an older study population.  
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A cross-sectional study of medication data from 23 nursing homes in Bergen, Norway, 
showed that psychotropic drugs were taken on a daily basis by as many as 59% of all 
residents, most commonly as long-term treatment (162).  
 
We are not sure whether drugs dispensed are actually used. However, our data is based on 
dispensed drugs rather than prescribed drugs and this rules out primary non-compliance, 
which is a problem with using prescribing data, for example, the United Kingdom General 
Practice Research Database (GPRD) (163, 164). Information on diagnosis or severity of the 
conditions treated is not available from NorPD. Categorising people according to drug 
treatment rather than medicinal diagnosis is not necessarily problematic or wrong, but 
knowing the diagnosis would be clarifying. There is an indistinct boundary between 
anxiolytics and hypnotics. Anxiolytics may be prescribed to aid sleep, meaning that in paper 
IV, people who used hypnotics at baseline may use anxiolytics instead during follow-up 
without changing diagnosis. Not all BZDs in Norway are anxiolytics and BZDs primarily 
used for indications other than anxiety were not included. Numerous non-hypnotic drugs are 
prescribed for insomnia in the USA (165), and there is as far as I know some prescribing of 
antidepressants and antihistamines for this indication in Norway (20). Further, there is an 
increasing prescribing of melatonin, the hormone regulating the body’s daily rhythm (96).    
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5.2.2 Information bias 
Information bias results from incorrect determination of exposure or outcome, or both (166). 
In a cohort study, if information is gathered differentially for the exposed than for the non-
exposed, then bias in one given direction results; whereas in contrast, non-differential 
misclassification; “noise in the system”, tends to obscure real differences (166).  
 
When using data from NorPD (papers II and part of paper IV), information bias is eliminated. 
In papers using data from health surveys (I, III and part of IV), answers to questions about 
drug use depend on the memory of the responders. Van den Brandt showed that recall of drug 
use decreased with increasing age and with increasing number of prescribed drugs per subject, 
but no difference in recall was observed between men and women (167). The time frame for 
recollection of drug use is crucial. Increasing the length of the period increases the risk for 
underreporting. The recall problem was thus assumed to be small in our health survey studies 
with a recall period of four weeks and since the population was 30-60 years old. Further, fixed 
questions on drug categories, as used in the health surveys, can be a tool to enhance memory. 
Additionally, there were perhaps a limited number of multi-drug users, due to the exclusion of 
certain groups of chronically ill subjects. A disadvantage of using shorter time periods is the 
under-representation of occasional users of drugs. Overall, the drug use questions did 
probably contribute to a high quality of information obtained and thus to an improved internal 
validity.  
 
The definition of drug use in studies mentioned in this thesis, varies from use during the last 
24 hours (24) to use during the last year (78). Ray et al studied the association of BZD use 
with fall risk, and by changing the definition of BZD use from “use the past week” at baseline 
to “use on a given day” during follow-up, the fall incidence rate ratio increased from 1.02 to 
1.44 (122). This was not related to memory, but was rather an example that, for drugs taken 
intermittently, asking for use before baseline reveals a risk of misclassification and further 
underestimation of associations.  
 
Overall, our estimates of psychotropic drug use based on health survey data may be too low, 
as drugs for psychological/psychiatric problems are particularly prone to underreporting 
(167), perhaps because of the stigma of mental illness. Underreporting of the frequency of 
drug use will likely bias the estimates towards the null.  
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5.2.3 Confounding 
Confounding is systematic error resulting from the fact that a secondary variable is linked 
both to the exposure and to the event of interest, which can wholly or partially explain their 
association (168). This can be taken into account or corrected for during the analysis. In this 
study, I addressed confounding by using multivariate and stratified analyses, either gender or 
age specific. In paper I, crude hazard ratios were markedly reduced, and for men the hazard 
ratio was no longer significant after the use of each of two adjustment models. This suggests 
that the remaining excess mortality is due to residual confounding, that is, if there were even 
more variables in the model, it is likely that the hazard ratios were even lower and not 
significant, also for women. 
 
Random error is the error that remains after the systematic errors described above (selection 
bias, information bias and confounding) are eliminated. This is the portion of variation in a 
measurement that has no apparent connection to any other measurement or variable, generally 
regarded as due to chance (155). This deviation results in a loss of precision, but is not 
systematic in a given direction. A common way to reduce random or sampling error, or to 
increase precision, is to enlarge the size of the study. The study population in our health 
surveys was large, and for analyses of subgroups of drug users, small sample size was not a 
problem. From the nationwide database NorPD, complete data were collected.  
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6.0 CONCLUDING REMARKS AND FURTHER PERSPECTIVES 
Anxiolytic or hypnotic drugs alone can probably never completely solve life crises, insomnia 
or anxiety. However they can be helpful for limited periods of time.  
 
The use of benzodiazepine (BZD) anxiolytics and hypnotics in Norway is reduced (Figure 1). 
However; owing to the increased use of antidepressants and z-hypnotics, it is likely that some 
of the quitters change over to these drugs. When working towards a reduction in the total use 
of psychotropic drugs, the recent experience made in Denmark is worth noting: The Institute 
of Rational Pharmacotherapy registered lower use of both anxiolytics, hypnotics in general 
and z-hypnotics after mass distribution of three brochures to physicians, their co-workers and 
inhabitants (169). Approximately 75% of the quitters did not compensate with another 
psychotropic drug (169).  
 
There has been and still is a lot of focus on BZD anxiolytics and hypnotics. As the total use 
decreases, the population using it becomes more selected. There could be reason to believe 
that the aspects of dependence and abuse are likely to contribute to maintained interest.  
 
For z-hypnotics, we do not yet know all the aspects of use. The drugs were thought to be safer 
than BZDs, however, they can be abused as well (44). The question is perhaps not if the future 
will bring another new generation of anxiolytic and hypnotic drugs with less initial concern of 
use, but when this happens and what drugs will be a part of it. Melatonin or related drugs may 
play a more important role in the future. In Norway, the sale of melatonin (ATC code 
N05CH01) has increased almost 175% from 2004 to 2009 (2, 96).  
 
Some possible implications of the findings:
 The increased mortality found among users of anxiolytic or hypnotic drugs in a 
general middle-aged population can perhaps serve as a warning to prescribers that 
there are possible unwanted long-term consequences from the use of these drugs.  
 
 The choice of an optimal drug for each new patient with insomnia; a BZD or a z-
hypnotic, has to be concluded from what aspect is more important for the individual 
patient, such as acting time, co-morbidity, drug interactions and abuse potential. 
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 The association found between use of analgesics and anxiolytics/hypnotics among 
people with mental distress can make us ask whether pain for some people has led to 
mental distress and further treatment for this. Perhaps the methods used to relieve or 
cope with pain, both medical treatment and non-medical treatment, can be further 
optimized.   
 
 The association found between not participating in the labour market and the use of 
antidepressants among people with mental distress can lead to a “chicken and egg” 
dilemma: What happened first; receiving social support or becoming depressed? There 
is reason to believe people’s health, both mental and somatic, could benefit from 
going to work either full or part time, with adjusted tasks if needed. Such a practice 
can be a challenge in a society that requires increasing effectiveness; however in the 
end it may even be cost-effective.  
 
 Mental distress was found to be related to later use of anxiolytic drugs in a dose 
response manner among middle-aged people. Theoretically, GPs’ screening of middle-
aged people using HSCL-10 would tell us where to put the effort in order to prevent 
later mental health problems which demand medical treatment. In practice, far from all 
middle-aged people visit a GP regularly. Inviting them to visit a GP in order to reveal 
mental distress would perhaps not give the optimal participation. A relevant question 
is whether GPs can be more effective at picking up mental health problems even if 
people visit them for other reasons.    
 
 Gender differences were observed for mortality, prevalence and incidence rates. 
Women showed a higher proportion of use than men for all the studied drug groups: 
anxiolytics, BZD hypnotics, z-hypnotics and antidepressants. Researchers have 
questioned whether women suffer from more pain than men, if they complain more, or 
if the truth is a combination of the two arguments. We found that among people with 
mental distress, the OR of later filling prescriptions on anxiolytics was quite similar 
for the two genders within age groups, whereas the level of use was higher in women.  
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Interestingly, when studying the Norwegian counties separately there are large differences in 
the number of filled prescriptions of anxiolytic and hypnotic drugs. In the county with the 
highest use of anxiolytics the one year prevalence of use, age-adjusted to the Norwegian 
population 2009 for men and women separately, was two times that of the lowest (29). For 
BZD hypnotics, the county with highest use had a one year prevalence three times that of the 
lowest for both sexes. For z-hypnotics the county with highest use showed a one year 
prevalence one and a half times that of the lowest. These differences are comparable to or 
larger than those existing between the Nordic countries.  
 
Perhaps there are significant health differences between counties. Further, there may be 
geographically different therapy traditions, which are sustained although prescribers can 
move between counties and countries and in the end are replaced by new generations. The 
possible difference between rural and urban populations is another factor that makes me 
curious of even more aspects of the epidemiology of anxiolytic and hypnotic drug use in 
Norway.  
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8.0 ERRATA  
 
Synopsis of papers: Paper II 
Results, 2nd bullet point: 
Of the 73 163 (not 73 173) incident users…  
Paper I 
Page 914, Materials and methods:  
The total response rate was high; 72.0% (not 72.1%) for men and 80.8% (not 80.1%) for 
women. All participants who were medically examined got this questionnaire and 82% of 
them responded (not 69%). The additional questionnaire included a question covering use of 
anxiolytics and hypnotics, which was answered by as many as 85% (men) and 83% (women) 
of the responders (not 98%). 
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APPENDICES 
Appendix I:   The Østfold Health Study 1985/1988 
The Aust-Agder Health Study 1986/1989
 Main questionnaire 1985 and 1986 
 Main questionnaire 1988 and 1989 
 Supplementary questionnaire 1985 and 1986 
 Supplementary questionnaire 1988 and 1989 
Appendix II:   The Oslo Health Study (HUBRO) 2000-2001 
The Health Study in Oppland and Hedmark (OPPHED) 2000-2001 
 Main questionnaire (Norwegian) 
 Main questionnaire (English)
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